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ABSTRACT  
   
Background: Despite the reported improvements in glucose regulation associated 
with flaxseeds (Linum usitatissimum) few clinical trials have been conducted in diabetic 
participants. Objective: To evaluate the efficacy of ground flaxseed consumption at 
attenuating hyperglycemia, dyslipidemia, inflammation, and oxidative stress as compared 
to a control in adults with non-insulin dependent type 2 diabetes (T2D). Design: In a 
randomized parallel arm controlled efficacy trial, participants were asked to consume 
either 28 g/d ground flaxseed or the fiber-matched control (9 g/d ground psyllium husk) 
for 8 weeks. The study included 17 adults (9 male, 8 females; 46±14 y; BMI: 31.4±5.7 
kg/m2) with a diagnosis of T2D ≥ 6 months. Main outcomes measured included:  
glycemic control (HbA1c, fasting plasma glucose, fasting serum insulin, and HOMA-IR), 
lipid profile (total cholesterol, LDL-C, HDL-C, total triglycerides, and calculated VLDL-
C), markers of inflammation and oxidative stress (TNF-alpha, TBARS, and NOx), and 
dietary intake (energy, total fat, total fiber, sodium). Absolute net change for measured 
variables (week 8 values minus baseline values) were compared using Mann-Whitney U 
non-parametric tests, significance was determined at p ≤ 0.05. Results: There were no 
significant changes between groups from baseline to week 8 in any outcome measure of 
nutrient intake, body composition, glucose control, or lipid concentrations. There was a 
modest decrease in TNF-alpha in the flaxseed group as compared to the control (p = 0.06) 
as well as a mild decrease in TBARS in the flaxseed as compared to the control group (p 
= 0.083), though neither were significant. Conclusions: The current study did not detect a 
measurable association between 28 g/d flaxseed consumption for 8 weeks in T2D 
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participants and improvements in glycemic control or lipid profiles. There was a modest, 
albeit insignificant, decrease in markers of inflammation and oxidative stress in the 
flaxseed group as compared to the control, which warrants further study.  
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
According to the Center for Disease Control (CDC) national diabetes statistics report, in 
2014 alone 29.1 million, or 9.4%, of the adult population in the U.S. had diabetes (CDC, 
2015). In 2012 alone there were 1.7 million newly diagnosed cases of diabetes in persons 
over the age of 20.  Additionally, the American Diabetes Association (ADA) estimated 
that in 2012 37% of U.S. adults aged 20 years or older were considered prediabetic, 
which if left unresolved can progress into type 2 diabetes (T2D). The enormous 
economic burden as a result of the increasing prevalence of diabetes is estimated to be 
$245 billion dollars in both direct and indirect costs with direct costs estimated at $176 
billion and indirect costs, such as disability or missed days of work, approximated at $69 
billion (ADA, 2013). Moreover, 35.7% of the U.S. population is currently obese, which 
is expected to contribute to a rise in individuals diagnosed with T2D. T2D is 
independently associated with an increased risks for cardiovascular diseases (CVD) 
(Taub et al. 2013), which is primarily due to the early development of advanced 
atherosclerotic vascular changes (Naka et al. 2012). The mechanisms underlying the 
association of T2D with vascular dysfunction are considered to be complex. Classical 
cardiovascular risk factors (hypertension, dyslipidemia and smoking) may play a role, 
while diabetes-related parameters such as hyperglycemia and insulin resistance interpose 
increased risk to impaired vascular function. Obesity, and other associated emerging risk 
factors such as inflammation, may also contribute to the impairment of arterial function 
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in T2D (Lowe et al. 2013; Paneni et al. 2014; Theuma and Fonseca, 2003). The relative 
importance of these risk factors in the induction of vascular dysfunction in T2D patients 
has not been well-studied. Prolonged hyperglycemia, elevated blood glucose, is the 
hallmark of diabetes and results in the glycosylation of hemoglobin molecules (HbA1c), 
elevations of which can be used as biomarkers of glycemic control over the prior 2-3 
months. This leads to oxidative stress and inflammation, both of which contribute to the 
development of renal failure, blindness, and cardiovascular disease (Rolo and Palmeira, 
2006). Oxidative stress may also contribute to hypertension by reducing the 
bioavailability of the vasodilator nitric oxide, resulting in impaired endothelium-
dependent vasodilation, which can be reversed with antioxidants (Bajaj and Khan, 2012). 
Additionally, T2D is associated with lipid abnormalities characterized by high 
triglyceride concentrations, reductions in high density lipoprotein-cholesterol (HDL-C) 
concentrations, and increases in low density lipoprotein-cholesterol (LDL-C) 
concentrations. Increases in small, dense proatherogenic LDL-C particles are frequently 
observed in T2D (Lukic et al. 2014). Most of the lipid abnormalities in T2D can be 
explained by reduced action of insulin at the tissue level (Reaven, 2011). Previous 
research has established a link between high concentrations of LDL-C and CVD (Wing 
et al. 2011).  Most patients with diabetes require diet and/or hypoglycemic medications 
to regulate their blood glucose (CDC, 2012) often resulting in little success. Moreover, 
costly hypoglycemic medications are often associated with complications including 
gastrointestinal distress, lactic acidosis and hepatotoxicity (Qaseem et al. 2012). Data has 
also indicated that T2D is a strong predictor of complications associated with 
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hypertension and other cardiovascular disease risk factors. Approximately 67% of T2D 
adults have an average resting blood pressure of ≥ 140 mm Hg (defined as hypertensive) 
(Ferrannini et al. 2012). Therefore, simple and inexpensive dietary strategies for the 
control of diabetes would be welcomed by patients and medical professionals and may 
help to reduce the economic burden related to both direct and indirect costs of this 
devastating illness within the United States as well as globally if widely-implemented.  
Studies have shown that individuals who consume diets high in fibers such as 
psyllium and beta-glucan have decreased oxidative stress and inflammation along with 
improved lipoprotein profiles (Satija and Hu, 2012). While research has focused on the 
health benefits of plant-based fibers such as psyllium at reducing symptoms of T2D and 
cardiovascular disease, to our knowledge, no studies have examined the potential 
therapeutic benefits of flaxseed-derived fiber supplementation in the control of T2D in 
regards to endothelial function and inflammation. Moreover, a comparison of flaxseed-
derived versus pysllium-based fibers on diabetic complications, including cardiovascular 
disease, has not been performed.  
The majority of studies on flaxseeds have focused on the effects of the oil, which 
even at high doses (10g/day) reportedly has no impact on blood glucose, HbA1c, insulin 
concentrations or lipid profiles (Barre et al. 2008). In contrast, a recent study concluded 
that daily supplementation of ground flaxseeds (10g/day) in adults with T2D for just one 
month significantly reduced fasting blood glucose by 19.7%, HbA1c by 15.6%, in 
addition to improvements in lipid regulation (Mani et al. 2011). Moreover, recent 
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research has indicated that 40 g/d of flaxseed meal lead to significant improvements in 
lipid profiles in adult males with hypercholesterolemia (Pan et al. 2007).  
 
 
1.2 Purpose of Study 
The purpose of this pilot study and efficacy trial is to compare the effectiveness of eight 
weeks of 28 g/d ground flaxseed supplemented to an individual’s habitual diet as 
compared to a standardized amount of psyllium fiber (9 g/d) on management of 
symptoms associated with T2D including glucose homeostasis, dyslipidemia, oxidative 
stress, inflammation, and blood pressure in subjects with non-insulin dependent T2D.  
 
1.3 Specific Aims and Hypotheses  
The hypothesis for this study is that there will be no significant difference in participants 
with non-insulin dependent T2D who supplement their normal diet with 28 g/d of ground 
flaxseed versus 9 g/d of psyllium on glycemic regulation, serum lipids, and 
concentrations of inflammatory as well as markers of oxidative stress.  We will test this 
hypothesis through three specific aims. 
 
Specific Aim 1: To compare the effectiveness of daily flaxseed (28 g/d) or psyllium (9 
g/d) supplementation on improvements in acute and chronic glycemic control in adults 
with non-insulin dependent T2D. Hypothesis: Adults with T2D consuming 28g/d of 
ground flaxseeds for 8 weeks will have reduced fasting blood glucose, insulin, HbA1c, 
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and homeostatic model assessment of insulin resistance (HOMA-IR), compared to 
matched subjects consuming 9 g/d pysllium supplementation.  
 
Specific Aim 2: To compare the effectiveness of daily flaxseed (28 g/d) or psyllium (9 
g/d) supplementation on improvement in lipid profiles. Hypothesis: There will be no 
difference in total cholesterol, LDL-C, HDL-C, total triglycerides, VLDL-C, or 
HDL:LDL ratios in adults with T2D consuming 28 g/d of ground flaxseed as compared to 
matched subjects for 8 weeks will have a significantly lower total cholesterol, total 
triglycerides, and LDL-C as well as an improved LDL:HDL ratio as compared to 
matched subjects consuming a supplement with a similar fiber content (9 g/d psyllium 
husk). 
 
Specific Aim 3: To compare the effectiveness of daily flaxseed (28 g/d) or psyllium (9 
g/d) supplementation on improvements in markers of vascular reactivity through 
increased nitric oxide availability as well as diminished oxidative stress and inflammation 
in adults with non-insulin dependent T2D. Hypothesis: There will be no significant 
difference in improvements of  vascular health (reduced blood pressure and increased 
plasma nitric oxide),  reductions of markers of oxidative stress and inflammation (lipid 
peroxidation, and TNF-α) between the non-insulin dependent T2D participants in the 
flaxseed group (28 g/d)  as compared to the psyllium group (9 g/d) from baseline to week 
8.   
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1.4 Impact 
The results of this study are expected to have a broad impact by contributing to the 
understanding of how flaxseed supplementation may improve vascular health in diabetes 
as well as provide a potential cost-effective nutrition-based alternative for glucose 
regulation that may help to alleviate the costly burden of medication to individuals 
suffering from diabetes.  
 
1.5 Delimitations and Limitations 
Possible limitations of this study include lack of adequate sample size to achieve power 
(set at 80%). To avoid these potential complications we performed a sample size power 
analysis based upon an extensive literature review (see section 3.6). Additionally, we 
modified the amount of test foods for both treatment and control groups to represent 
moderate intake that more accurately reflect a participant’s average diet in an effort to 
increase compliance. Anticipated problems include contamination of samples which will 
be avoided by utilizing rigorous laboratory techniques and by wearing personal protective 
equipment at all times. There is also a potential problem in tissue availability which will 
be overcome by optimizing assays through proper collection and storage of tissue 
samples, using aliquoted samples to prevent protein degradation, and determining 
appropriate collected sample (i.e., plasma versus serum) to use for each parameter, and 
by using commercially available kits which have been previously validated for 
sensitivity, specificity, accuracy, precision, detection limit, range and limits of 
quantitation. Standard curves were also performed an analyzed during each assay, 
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according to the manufacturers protocol to ensure inter-assay and inter-laboratory 
assessment of assay and to increase the repeatability and robustness of the results. 
 
Delimitations of the study are that the data will be generalizable only to adults with non-
insulin dependent T2D. Data will also not provide information on direct measurements of 
vascular dysfunction or small resistance arteries which are important in blood pressure 
regulation and microvascular complications associated with T2D.  
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Definition of Terms 
Adenosine Diphosphate (ADP)- a nucleotide composed of adenine, ribose, and two 
phosphate groups that functions in the transfer of energy during the catabolism of 
glucose, formed by the removal of a phosphate group from adenosine triphosphate.  
Adenosine Triphosphate (ATP)- a high energy molecule which consists of adenosine, 
ribose, and three phosphate groups. It is the primary source of energy in cellular 
metabolism due to its ability to donate a phosphate group during biochemical reactions. 
Adipokines- Cytokines secreted by adipose tissue.   
Adiponectin- A 244 amino acid polypeptide involved in regulating glucose 
concentrations as well as fatty acid breakdown.      
Adipose Tissue Macrophages (ATMs)- Macrophages present in adipose tissue.  
Angiotensin Converting Enzyme (ACE)- A glycoprotein (dipeptidyl carboxypeptidase) 
that catalyzes the conversion of angiotensin I to angiotensin II by splitting two terminal 
amino acids. ACE-inhibiting agents are used for controlling hypertension and for 
protecting the kidneys in diabetes mellitus.        
Angiotensin II (AII)- An octapeptide that is a potent vasopressor and powerful stimulus 
for production and release of aldosterone from the adrenal cortex.    
Arteriosclerosis- A condition in which an artery wall thickens as a result of the 
accumulation of fatty materials such as cholesterol and triglyceride. It is a syndrome 
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affecting arterial blood vessels, a chronic inflammatory response in the walls of arteries, 
caused largely by the accumulation of macrophages and promoted by low-density 
lipoproteins.   
C-Reactive Protein (CRP)- A protein found in the blood, the levels of which rise in 
response to inflammation (acute phase protein).     
Cytokine- Small signaling molecules used for cell signaling. Cytokines can be classified 
as proteins, peptides, or glycoproteins.      
Diabetes- A group of metabolic diseases in which a person has high blood sugar, either 
because the pancreas does not produce enough insulin, or because cells do not respond to 
the insulin that is produced.       Dyslipidemia- 
An abnormal amount of lipids (e.g. cholesterol and/or fat) in the blood.  
Dyspnea- Shortness of breath.        
Electron Transport Chain (ETC)- an enzymatic series of electron donors and acceptors 
located within the mitochondria of eukaryotic cells  that transfer electrons from electron 
donors to electron acceptors via redox reactions, and couples this electron transfer with 
the transfer of protons (H+ ions) across a membrane which drives the synthesis of ATP.  
Endocrine System- The collection of cells, glands, and tissues of an organism that 
secrete hormones directly into the bloodstream to control the physiological and 
behavioral activities of an organism.         
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Endothelin 1 (ET-1)- A protein peptide that is a potent vasoconstrictor produced by 
vascular endothelial cells.          
Endothelium- the thin layer of endothelial cells that line the interior surface of blood 
vessels forming an interface between circulating blood in the lumen and the rest of the 
vessel wall. Endothelial cells line the entire circulatory system, from the heart to the 
capillaries. Functions include fluid filtration (such as in the glomeruli of the kidney), 
blood vessel tone, hemostasis, neutrophil recruitment, and hormone trafficking. 
Fatty Acid Oxidation- (beta-oxidation) The process by which fatty acid molecules are 
broken down in the mitochondria to generate acetyl-coA, which enters the citric acid 
cycle, and NADH and FADH2, which are used by the electron transport chain.  
Fibroblasts- A type of cell that synthesizes the extracellular matrix and collagen; the 
structural framework (stroma) for animal tissues; and plays a critical role in wound 
healing. Fibroblasts are the most common connective tissue in animals. 
Gluconeogenesis (GNG)- A metabolic pathway that generates glucose from non-
carbohydrate carbon substrates such as pyruvate, lactate, glycerol, gluconeogenic amino 
acids, and medium-chain fatty acids.      
Glucose- A six carbon (hexose) sugar molecule that serves as the principle source of 
sugar in the blood and a major source of metabolic energy.   
Glucose Transporters- A diverse family of membrane proteins that facilitate the 
transport of glucose over a plasma membrane.      
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Glycogenolysis- Breakdown of glycogen to glucose-1-phosphate and glucose. Glycogen 
branches are catabolized by the sequential removal of glucose monomers via 
phosphorolysis, by the enzyme glycogen phosphorylase.  
Glycolysis-The catabolism of carbohydrates such as glycogen and glucose by enzymes 
into pyruvate or lactic acid resulting in the release of energy.  
Hemoglobin A1c (HbA1C)- A form of hemoglobin that is measured primarily to 
identify the average plasma glucose concentration over prolonged periods of time (i.e. 
prior 90 days). It is formed by non-enzymatic binding of glucose to hemoglobin.  
      
Hyperglycemia- A condition in which an excessive amount of glucose circulates in the 
blood plasma (fasting plasma glucose >100 mg/dl or non-fasting plasma glucose >140 
mg/dl).           
Hyperplasia- An increase in cell number.       
Hypertrophy- An increase in cell size.       
Hypoxia- A pathological condition in which the body or a region of the body is deprived 
of an adequate oxygen supply.       
Hypoxia Inducible Factor 1 alpha (HIF-1 alpha)- a protein regulated by nuclear factor-
kappa B in response to hypoxia. 
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Impaired Fasting Glucose (IFG)- A condition in which fasting blood glucose 
concentrations are consistently elevated above what is considered physiological.  
 Impaired Glucose Tolerance (IGT)- A sustained hyperglycemic response during 
a glucose challenge.   
Infarction- Tissue death (necrosis) caused by a lack of oxygen, due to an obstruction of 
blood flow in a tissue.     
Inflammation- Part of the complex biological response of vascular tissues to harmful 
stimuli such as pathogens, damaged cells, or irritants. Inflammation is a protective 
attempt by the organism to remove the injurious stimuli and to initiate the healing 
process.    
Innate Immune System- The first line of defense of the immune system response, 
comprises the cells and mechanisms that defend the host from infection by other 
organisms in a non-specific manner (i.e. not requiring the production of antibodies).  
Insulin Resistance- A physiological condition in which cells fail to respond to the 
normal actions of the hormone insulin.      
Interleukin 1 beta (IL-1 beta)- A cytokine mediator of the inflammatory response. It is 
also involved in a variety of cellular activities including cell proliferation, differentiation, 
and apoptosis.      
Interleukin 6 (IL-6)- Secreted by T cells and macrophages to stimulate immune 
responses. Acts in both pro-inflammatory and anti-inflammatory capacities.  
13 
 
Interleukin 8 (IL-8)- a chemokine secreted by any cells with toll-like receptors that are 
involved in the innate immune response.     
Islets of Langerhans- Irregular clusters of endocrine cells scattered throughout the tissue 
of the pancreas that secrete insulin and glucagon.     
Leptin- A 16-kDa protein hormone that plays a key role in regulating energy intake and 
expenditure including appetite and hunger, metabolism, and behavior.  
Lipogenesis- The process by which acetyl-CoA is converted to fatty acids. 
Lipolysis- The breakdown of lipids. It involves hydrolysis of triglycerides into glycerol 
and free fatty acids.           
Macrophages- Immune cells produced by the differentiation of monocytes that are 
responsible for ingesting and breaking down pathogens.  
Metabolic Syndrome (MetS)- A disorder of energy utilization and storage, diagnosed by 
a co-occurrence of three out of five of the following medical conditions: abdominal 
(central) obesity, elevated blood pressure, elevated fasting plasma glucose, high serum 
triglycerides, and low high-density cholesterol (HDL-C) levels. Metabolic syndrome 
increases the risk for developing cardiovascular disease.    
Monocyte Chemoattractant Protein 1 (MCP1)- recruits monocytes, memory T cells, 
and dendritic cells to the sites of inflammation produced by either tissue injury or 
infection.   
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Nitric Oxide- A potent vasodilator.       
Nitric Oxide Synthases- A family of enzymes that catalyze the production of nitric 
oxide (NO) from L-arginine.         
Non-Alcoholic Hepatic Steatosis- Accumulation of fat in the liver; may progress to non-
alcoholic fatty liver disease (NAFLD).        
Normoglycemia- Blood glucose concentrations that fall within the normal range of <100 
mg/dl fasting, <140 mg/dl 2 hours after a high load glucose challenge, or an A1C <6.0%. 
Oxidative Stress- A situation in which there is an increase in free radicals caused by 
either increased production of oxidizing species or a significant decrease in the 
effectiveness of antioxidant defenses.  
Perivascular Adipose Tissue (PVAT)- Adipose tissue surrounding blood vessels. 
Polydipsia- Excessive thirst.        
Polyphagia- Excessive hunger.       
Polyuria- Excessive urination.      
Preadipocytes- Undifferentiated fibroblasts that can be stimulated to form mature 
adipocytes. 
Prediabetes- The state in which some but not all of the diagnostic criteria for diabetes 
are met.  
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Preproinsulin- the precursor of proinsulin which contains an additional polypeptide 
sequence at the N-terminal which are then removed by proteases in the endoplasmic 
reticulum to form proinsulin. 
Reactive Oxygen Species- Chemically reactive molecules containing oxygen. 
Resistin- A cysteine-rich adipokine implicated in the etiology and progression of obesity 
and type 2 diabetes. Resistin accelerates the accumulation of LDL in arteries, increasing 
the risk of heart disease.    
Sleep Apnea- A sleep disorder characterized by pauses in breathing or instances of 
shallow or infrequent breathing during sleep.    
Superoxide (O2˙ˉ)- A free radical product of the one-electron reduction of dioxygen.  
The Citric Acid Cycle (TCA or Krebs cycle)- A  major metabolic pathways of cellular 
respiration, and involves a cyclic series of enzymatic reactions by 
which pyruvate converted into Acetyl Coenzyme A is completely oxidized to 
CO2 and hydrogen is removed from the carbon molecules, transferring 
the hydrogen atoms and electrons to electron-carrier molecules (e.g. NADH and FADH2) 
as well as the synthesis of ATP.  
Toll-Like Receptors (TLRs)- A class of proteins that play a key role in the innate 
immune system. They are single, membrane-spanning, non-catalytic receptors usually 
expressed in sentinel cells such as macrophages and dendritic cells that recognize 
structurally conserved molecules derived from microbes.   
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Tumor Necrosis Factor Alpha (TNF-alpha)- An adipokine involved in systemic 
inflammation that stimulates the acute phase reaction.       
Type 2 Diabetes (T2D)- Disease state characterized by insulin resistance, sometimes 
combined with an absolute insulin deficiency. This form of diabetes was previously 
referred to as non insulin-dependent diabetes mellitus (NIDDM) or "adult-onset 
diabetes".        
Vascular Endothelial Growth Factor (VEGF)- A signal protein produced by cells that 
stimulates vasculogenesis and angiogenesis.   
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CHAPTER 2 
REVIEW OF LITERATURE 
2.1 Glucose Metabolism  
2.1.1 Glucose  
Glucose metabolism is critical to normal physiological functioning.  Glucose is the 
human body's key source of energy, providing about four calories per gram through 
aerobic respiration. Breakdown of carbohydrates (e.g. starch) yields mono-
 and disaccharides, most of which is glucose. Through glycolysis and later in the 
reactions of the  tri-carboxylic acid (TCA) cycle, glucose is oxidized to eventually 
form CO2 and water, yielding energy mostly in the form of adenosine tri-phosphate 
(ATP) which is required for nearly all types of cellular reactions. Normal plasma glucose 
concentration varies between about 70 and 120 mg/dL (3.9-6.7 mM) (Mantzoros et al. 
2011). The brain uses about 120 grams of glucose daily which is approximately 60-70% 
of the total body glucose metabolism (Bergman, 2013). However, the brain has little 
stored glucose and no other energy stores, making glucose an essential nutrient for 
survival. Brain function begins to become seriously affected when glucose levels fall 
below 40 mg/dL; levels of glucose significantly below this can lead to permanent damage 
and death (Levin, 2002). The brain cannot use fatty acids for energy due to the inability 
of fatty acids to cross the blood-brain barrier. Ketone bodies such as acetoacetate and 
hydroxybutyrate, which are produced as by-products of beta-oxidation derived acetyl-
CoA being further metabolized in the TCA metabolic pathway, can however be utilized 
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by the brain for energy in emergencies such as periods of severely restricted carbohydrate 
or food intake. 
 
2.1.2 Glucose Homeostasis  
Glucose entry into cells is facilitated by a family of glucose transporter proteins 
(GLUT). The most commonly identified glucose transporters are GLUT1-5, each of 
which exhibit different affinities for various monosaccharides and display tissue-specific 
expression (Zhao and Keating, 2007). These characteristics contribute to how the various 
tissues respond to glucose. Typically, glucose transporters are localized on the plasma 
membrane and allow for glucose to enter the cell in a passive diffusion manner (Klip and 
Pâquet, 1990). However, the glucose transporter isoform 4 (GLUT4), is located in 
intracellular membrane vesicles which must be stimulated through an insulin mediated 
cell signaling cascade and undergo cellular trafficking to the membrane surface (Russell 
et al. 1999). The GLUT4 isoform, which is specifically expressed in insulin sensitive 
tissues such as skeletal muscle, heart muscle, and fat, is responsible for insulin-mediated 
blood glucose clearance (Saltiel and Kahn, 2001).Various organs function to regulate 
circulating glucose levels in the plasma including the liver, brain, pancreas, skeletal 
muscle, adipose tissue, heart, and kidneys. There are two main endogenous metabolic 
pathways which function to regulate glucose levels, gluconeogenesis and glycogenolysis. 
Gluconeogenesis (GNG) is a metabolic pathway that results in the generation 
of glucose from non-carbohydrate carbon substrates such as pyruvate, lactate, glycerol 
(derived from odd-chain fatty acids and to a lesser extent long-chain fatty acids)  in 
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addition to glucogenic amino acids. The liver and kidneys are the main organs which 
contribute to the GNG pathway. When circulating blood glucose concentrations are too 
low (hypoglycemia) the body acts to increase glucose levels through the breakdown 
of glycogen via glycogenolysis. Glycogenolysis functions to catabolize glycogen, the 
stored glucose energy source in liver and skeletal muscle, to glucose-1 phosphate which 
is then readily available to provide energy for intracellular processes.  
The diet is an abundant source of circulating glucose and provides carbon and 
energy sources for liver gluconeogenesis. The liver is the major metabolic regulatory 
organ for glucose metabolism. About 90% of all circulating glucose not derived directly 
from the diet comes from the liver (Schwarz et al. 1995). The liver contains significant 
amounts of stored glycogen available for rapid release into circulation and is capable of 
synthesizing large quantities of glucose from substrates such as lactate, amino acids, and 
glycerol released by other tissues. In addition to controlling plasma glucose, the liver is 
responsible for synthesis and release of the lipoproteins that adipose and other tissues use 
as the source of cholesterol and free fatty acids (Weikert and Pfieffer, 2006). During 
prolonged starvation, the liver is the source of both glucose and ketone bodies that are 
required by the brain to maintain function. Like the liver, the kidney has the ability to 
release glucose into the blood. Under normal conditions gluconeogenesis in the kidneys 
provides only a small contribution to the total circulating glucose; however, during 
prolonged starvation, the contribution of the kidneys to circulating glucose may approach 
that of the liver (Stumvoll et al. 1998). Kidney function is critical for glucose homeostasis 
for another reason; plasma glucose continuously passes through the kidney and must be 
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efficiently reabsorbed to prevent loss. Skeletal muscle cannot release glucose into 
circulation; however, it has the ability to rapidly increase glucose uptake in response to 
sudden elevations in circulating plasma glucose as is the case after a meal or during 
periods of increased demand, such as during an acute bout of exercise (Rose and Richter, 
2005). Adipose tissue also acts as a major site of glucose metabolism. Insulin stimulates 
glucose uptake into adipose tissue, and has three major actions which result in net fat 
deposition: 1) insulin increases the amount of lipoprotein lipase, an enzyme that mediates 
release of free fatty acids from circulating lipoproteins; 2) insulin stimulates synthesis of 
glycerol-phosphate (required for triacylglycerol synthesis) from glucose; and 3) insulin 
inhibits hormone-sensitive lipase, the enzyme responsible for the first step in 
triacylglycerol breakdown (Odegaard and Chawla, 2013). Adipose tissue is the major site 
of fatty acid storage. Fatty acids are stored in the form of triacylglycerol, which is 
synthesized from glycerolphosphate and free fatty acids. The glycerol-phosphate used 
must be derived from glycolysis in the adipose tissue; free glycerol cannot be 
phosphorylated because adipocytes lack the relevant kinase (Guo et al. 2013). In 
conditions when liver gluconeogenesis is necessary the adipose tissue supplies free fatty 
acids and glycerol into the circulation to be taken up by the liver as substrate. Finally, the 
pancreas is the source of insulin and glucagon, two of the most important metabolic 
regulatory hormones.  
 
2.2 Regulation of Post-Prandial Glucose Metabolism 
2.2.1 Endocrine regulation of glucose metabolism 
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Insulin is an anabolic hormone secreted by the pancreas essential for appropriate tissue 
development and growth. Insulin also functions to regulate circulating glucose levels in 
response to a meal (Pessin et al. 2000).  Insulin plays a major role in the metabolism of 
carbohydrates and lipids (McGarry and Foster 1980). The pancreas alters its release of 
insulin and glucagon in response to changes in plasma glucose and other circulating 
nutrients such as amino acids and free fatty acids. The response to a meal varies 
significantly depending on the composition of nutrient intake. The release of insulin 
levels caused by actually eating is thought to be due to gastrointestinal peptide hormones 
such as cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1), and ghrelin (Weir et al. 
2012). These peptides are released in response to food absorption and function to mediate 
the glucose effect on insulin release.  
When eating a meal rich in carbohydrates, insulin levels rise and glucagon levels 
fall (Thorens et al. 2011). The decrease of glucagon is due to inhibition of its release by 
insulin, and to the elevation in plasma glucose. When eating a meal rich in protein, 
insulin levels rise, because insulin secretion is stimulated by amino acids as well (Salehi 
et al. 2012). The release of glucagon in response to a meal high in protein functions to 
counteract the effects of insulin in order to maintain proper circulating glucose levels and 
avoid hypoglycemia due to the low carbohydrate content of the meal. When eating a 
mixed meal, insulin levels rise, and glucagon levels rise, fall, or remain unchanged as 
appropriate to maintain plasma glucose.  
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2.2.2 Mechanism of insulin  
Insulin is a hormone that is exclusively produced by pancreatic beta cells. Beta cells are 
located in the pancreas in clusters known as the islets of Langerhans. Insulin is a small 
protein and is produced as part of a larger protein to ensure it folds properly. In the 
protein assembly of insulin, the messenger RNA transcript is translated into an inactive 
protein called preproinsulin (Fu et al. 2013). Preproinsulin contains an amino-terminal 
signal sequence that is required in order for the precursor hormone to pass through the 
membrane of the endoplasmic reticulum (ER) (Leem and Koh, 2011) for post-
translational processing to proinsulin which is further modified to active insulin (Guo et 
al. 2014). Finally, insulin is packaged and stored in secretory granules, which accumulate 
in the cytoplasm, until release is triggered. 
 
2.2.3 Insulin secretion 
Insulin is released from beta cells, in response to changes in blood glucose concentration. 
Type 2 glucose transporters (GLUT2) mediate the entry of glucose into beta cells (Luni et 
al. 2012). Glucose (C6H12O6) enters the glycolysis pathway, which is the metabolic 
pathway responsible for converting glucose to pyruvate (CH3COCOO− + H+) and 
subsequent high energy compounds adenosine triphosphate (ATP) and reduced 
nicotimamide adenine dinucleotide (NADH). Glucose is phosphorylated by the rate-
limiting enzyme in this pathway, glucokinase. Upon modification glucose becomes 
trapped within the beta cells and is further metabolized to create ATP (Richter et al. 
2013). The increased in ATP to adenosine diphosphate (ADP) moleculares (ATP:ADP 
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ratio) causes the ATP-gated potassium channels in the cellular membrane to close, 
preventing potassium ions from crossing the membrane (Masini et al, 2014). The increase 
in potassium ions within the cell leads to an intracellular positive charge resulting in 
subsequent depolarization of the cell. This causes activation of voltage-gated calcium 
channels, which transport calcium ions into the cell. The increase in intracellular calcium 
concentrations results in the exportation, via exocytosis, of the insulin-storing granules 
from the beta cells and the diffusion of insulin into nearby blood vessels (Rorsman and 
Braun, 2013). There is a large and extensive vascular network which surrounds the 
pancreatic islets to ensure the adequate diffusion of insulin (and glucose) between beta 
cells and blood vessels (Dai et al. 2013).   
The release of insulin occurs in two stages. The initial amount of insulin released 
upon increases in circulating glucose is dependent on the available concentrations stored 
in the beta cells. Once these initial stores are depleted a second phase of insulin release is 
initiated. This latter release is prolonged since insulin has to be synthesized, processed, 
and secreted for the duration of the increase of blood glucose. Furthermore, beta cells 
also have to regenerate the stores of insulin initially depleted in the fast response phase. 
 
2.2.4 Functions of insulin and target tissues of insulin-mediated glucose disposal 
Insulin molecules circulate throughout the blood stream until they bind to their receptors 
(IR) located on various target tissues. Insulin regulates glucose disposal at many sites 
including the liver, skeletal muscles, adipose tissue (AT) and cardiac muscle (Olson and 
Pessin, 1996). In muscle and fat cells, the clearance of circulating glucose depends on the 
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insulin-stimulated translocation of the glucose transporter GLUT4 isoform to the cell 
surface which is initiated through activation of the IR. When insulin binds to its receptor 
on the cell membrane surface it activates the IR tyrosine kinase, which results in tyrosine 
phosphorylation of members of the insulin receptor substrate (IRS) family. Activation of 
the IR and IRS results in phosphorylation of the phosphatidylinositol 3-kinase (PI3K) 
pathway resulting in activation of protein kinase B (Akt) which functions to stimulate 
GLUT4 vesicles to the membrane surface. Insulin also functions to reduce hepatic 
glucose production and output (via decreased GNG and glycogenolysis) as well as 
increasing lipid synthesis in liver and adipocytes which result in attenuating fatty acid 
release from triglycerides in AT and muscle (Pessin et al. 2000). In a healthy person, 
these functions allow blood glucose and insulin levels to remain in the normal range. 
 
2.2.5 Impaired insulin signaling leading to insulin resistance 
The body’s regulation of glucose metabolism requires control and coordination of a series 
of complex mechanisms. Disruptions in normal insulin synthesis, secretion, regulation, or 
cell signaling lead to altered metabolism of glucose as well as lipids resulting in 
hyperglycemia and dyslipidemia. Impairments in normal insulin signaling are usually the 
result of genetic acquired traits, auto-immune disorders or environmental factors (Mlinar 
et al., 2007). In cases of type 1 diabetes mellitus, the body destroys insulin-producing 
beta cells in the pancreas, thus the individual does not produce insulin and must use an 
exogenous form. Other alterations in insulin signaling occur within the beta cells during 
synthesis and secretion, or at the post-receptor levels. At a molecular level insulin 
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resistance can be caused by impaired insulin signaling due to increased serine 
phosphorylation of the insulin receptor substrate-1 (IRS1). This change causes inhibition 
of IRS1 tyrosine phosphorylation, decreased binding of the downstream enzyme PI3K, 
and decreased phosphorylation and activation of the kinase Akt. IRS1 can be 
phosphorylated on serine residues by various isoforms of protein kinase C, which are 
activated by lipid intermediates, stress kinases, or increases in endoplasmic reticulum 
stress (Turban and Hujduch, 2011). The resulting hyperinsulinemia along with increases 
in inflammatory markers such as tumor necrosis factor alpha (TNF-alpha) and 
interleukin-6 (IL-6) may perpetuate the deregulation of Ser/Thr phosphorylation of IRS1 
and downstream signaling intermediates including PI3K (Rains and Jain, 2011).  
 
2.2.6 Insulin resistance and associated disorders  
Impaired insulin signaling is central to development of the insulin resistance, metabolic 
syndrome (MetS) as well as diabetes and can promote cardiovascular disease indirectly 
through development of abnormal glucose and lipid metabolism, hypertension, and 
inflammation. Insulin resistance in the liver is the major cause of fasting hyperglycemia 
due to increases in hepatic glucose output which is normally suppressed by insulin. 
Disrupted insulin signaling in the liver also contributes to dyslipidemia associated with 
hyperglycemia due to increases in fatty acid synthesis and decreased clearance of LDL 
and very low-density (VLDL) lipoproteins (Lukic et al. 2014). Moreover, impaired 
insulin signaling disrupts skeletal muscle glucose disposal due to decreased GLUT4 
expression through down-regulation of the insulin-mediated cell signaling cascade. In 
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addition to insulin resistance and hyperglycemia, dyslipidemia is a common characteristic 
of both MetS and T2D. Hepatic insulin resistance contributes to this dyslipidemia 
through increased fatty acid synthesis as well decreased clearance of LDL and very low-
density lipoprotein (Lukic et al. 2014). 
 
2.3 Insulin Resistance and Progression to T2D 
2.3.1 Insulin resistance 
Type 2 diabetes is a metabolic disorder that is characterized by high blood glucose in the 
context of insulin resistance and relative insulin deficiency (Kumar et al. 2008). Insulin 
resistance is a physiological condition in which cells fail to respond to the normal actions 
of the hormone insulin. In the context of insulin resistance, the body produces enough 
insulin in response to increases in glucose concentrations but its cells are too desensitized 
to allow adequate insulin signaling cascade response. Due to the ability to initially 
compensate for the lack of cell sensitivity and the need to maintain proper glucose 
homeostasis a person can still have glucose levels in the normal range as described 
below. Causes of insulin resistance may include ethnicity, certain diseases, excess 
weight, physical inactivity, hormones, steroid use, certain medications, age, and cigarette 
smoking. Mechanisms of insulin resistance as discussed in previous sections (2.2.5; 
2.2.6) include inhibition of IR, IRS, or insulin signaling intermediates. A person can be 
insulin resistant and still maintain normal blood glucose levels (normoglycemia) as long 
as the beta cells produce enough insulin to compensate for the decrease in cell sensitivity. 
Fluctuations in insulin sensitivity occur during the normal life cycle, with insulin 
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resistance being observed in puberty, pregnancy, and with aging (Moran et al. 1999, 
Buchanan et al. 1990). Conversely, lifestyle variations such as increased physical activity 
and increased carbohydrate intake are associated with increased insulin sensitivity (Musi 
and Goodyear, 2006). Thus, without lifestyle modifications (i.e., increased physical 
activity, improvements to diet) or medical interventions, insulin resistance will often 
progress to a condition known as prediabetes due to the high demand placed on the 
insulin-producing beta cells (McLellan et al. 2014). 
 
2.3.2 Metabolic syndrome, insulin resistance, and progression to T2D 
Insulin resistance is strongly associated with a condition known as MetS.  Prevalence of 
MetS in 2008, according to data from the National Health and Nutrition Survey Data Set 
(NHANES) was estimated at 34% of adults age 20 and older (Bassin et al. 2013). MetS is 
thought to represent a combination of cardiometabolic risk determinants, including 
obesity, glucose intolerance, insulin resistance, dyslipidemia (including 
hypertriglyceridemia, increased free fatty acids (FFAs) and decreased HDL-C) and 
hypertension. The concept of a cluster of metabolic abnormalities which predispose an 
individual to T2D and cardiovascular disease was first proposed by Eskil Kylin in the 
early 1900’s. Dr. Haller first used the term "metabolic syndrome" (MetS) to describe the 
association of obesity, diabetes mellitus (DM), hyperlipoproteinemia, hyperuricemia, and 
hepatic steatosis when describing the additive effects of risk factors on atherosclerosis.  
Dr. Gerald Phillips (1978) further developed the concept of metabolic risk factors for 
myocardial infarction and described a group of abnormalities including glucose 
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intolerance, hyperinsulinemia, hyperlipidemia, and hypertension. In 1988, Dr. Gerald 
Reaven proposed insulin resistance (IR) was the cause of glucose intolerance, 
hyperinsulinemia, increased (VLDL-C), decreased (HDL-C) and hypertension and named 
the constellation of abnormalities “syndrome X”. Multiple Health organizations including 
the World Health Organization (WHO), International Diabetes Federation (IDF), the 
European Group for the Study of Insulin Resistance, and the National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP III) all have varying 
definitions and diagnostic criteria for MetS (Miranda et al. 2005). However, the most 
common set of diagnostic criteria used to identify individuals with MetS in the U.S. by 
the American Heart Association and American Diabetes Association is the NCEP ATP 
III guideline which confirms MetS as having three or more of the following 
measurements present: 
• Abdominal obesity (waist circumference of 40 inches or above in men, and 35 
inches or above in women) 
• Triglyceride level of 150 milligrams per deciliter of blood (mg/dL) or greater 
• HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women 
• Systolic blood pressure (top number) of 130 millimeters of mercury (mm Hg) or 
greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater 
• Fasting glucose of 100 mg/dL or greater 
The associated complications of insulin resistance and MetS include atherosclerosis, 
coronary heart disease (CHD), non-alcoholic fatty liver disease (NAFLD), some cancers, 
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kidney dysfunction, pancreatic dysfunction, and polycystic ovarian syndrome (PCOS). 
While having insulin resistance and metabolic syndrome are risk factors for the 
development of prediabetes and T2D, it is not absolute. Moreover, it should be noted that 
while obesity appears to be a central factor in the development of both IR and MetS, 
normal weight individuals can develop either of these conditions or both independent of a 
being classified as overweight or obese (Park et al. 2003). 
 
2.3.3 Pre-diabetes 
In prediabetes, the beta cells can no longer produce enough insulin to overcome insulin 
resistance, causing blood glucose levels to rise above the normal range, known as 
impaired glucose tolerance (IGT). Prediabetes is a condition in which a person develops 
hyperglycemia (elevated blood glucose) or increased glycated hemoglobin (HbA1c) 
levels, which reflect average blood glucose levels over the prior 90 days, that are higher 
than normal but not high enough for a diagnosis of diabetes. A HbA1c of 5.7% to 6.4% 
indicates prediabetes. A fasting glucose level of 100 to 125 mg/dl indicates prediabetes 
and is known as impaired fasting glucose (IFG). A two hour sample of blood glucose 
level between 140 and 199 mg/dl for an oral glucose tolerance test, which measures 
blood glucose levels for up to 3 hours after a high glucose drink has been ingested 
indicates prediabetes. People with prediabetes are at increased risk of developing T2D 
and CVD, which can lead to heart attack or stroke (Ganguly et al. 2008). IR increases the 
risk of developing T2D and prediabetes (Cobb et al. 2013). Prediabetes usually occurs in 
people who already have insulin resistance. Although insulin resistance alone does not 
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cause T2D, it often contributes to the disease by placing a high demand on the insulin-
producing beta cells which eventually leads to the loss of adequate production as stated 
previously. 
 
2.3.4 Type 2 diabetes 
Once a person has prediabetes, continued loss of beta cell function usually leads to T2D 
(Ristow et al. 2004). Among those individuals who develop T2D, the proportion of IR 
versus beta cell dysfunction varies, with some having primarily insulin resistance and 
only a minor defect in insulin secretion and others with slight insulin resistance and 
primarily a lack of insulin secretion (Shoback et al. 2011). Other potentially important 
mechanisms associated with T2D and insulin resistance include increased breakdown of 
lipids within adipocytes, resistance to and lack of incretin (a gastrointestinal hormone that 
stimulate a decrease in blood glucose by causing an increase in the amount of insulin 
released from the beta cells after eating, before blood glucose levels become elevated), 
high glucagon levels in the blood that promote hyperglycemia, increased retention of salt 
and water by the kidneys, and inappropriate regulation of metabolism by the central 
nervous system (Smyth et al. 2006). People with T2D have hyperglycemia and, due to 
loss of insulin regulated lipid metabolism, elevated levels of non-esterified fatty acids 
(NEFA) (Tolman et al. 2007). Diagnosis for T2D as defined by the WHO includes a 
single raised glucose reading with classic symptoms including polyuria (frequent 
urination), polydipsia (increased thirst), polyphagia (increased hunger), and weight loss. 
Other symptoms that are commonly present at diagnosis include: a history of blurred 
31 
 
vision, itchiness, peripheral neuropathy, recurrent vaginal infections, and fatigue (ADA, 
2013). Additionally, diagnosis can be based from raised values on two occasions of 
either: a fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl) or plasma glucose 
concentrations ≥ 11.1 mmol/l (200 mg/dl) two hours after consuming a controlled dose of 
glucose during an oral glucose tolerance test (OGTT). A random blood sugar of greater 
than 11.1 mmol/l (200 mg/dl) in association with typical symptoms or HbA1c of greater 
than 6.5% are other diagnostic measures of diabetes. Over time, high blood glucose 
damages nerves and blood vessels, leading to complications such as CVD, stroke, 
blindness, kidney failure, neuropathies, and lower-limb amputations. IR and prediabetes 
often go unrecognized by patients until they have progressed to overt diabetes. People 
may have one or both conditions for several years without knowing they have them. 
 
2.4 Obesity and T2D 
2.4.1 Adipose tissue as an endocrine organ 
In addition to impairments in insulin signaling, accumulating AT and obesity are 
common factors in development of IR, T2D, and MetS. Adipose tissue (i.e., body fat) is 
composed mainly of adipocytes and connective tissue. In addition to adipocytes, AT 
contains the stromal vascular fraction (SVF) of cells including preadipocytes, fibroblasts, 
vascular endothelial cells and a variety of immune cells (i.e. AT macrophages (ATMs)). 
Adipose tissue is derived from preadipocytes. Adipose tissue is found in specific 
locations, which are referred to as adipose depots. In humans, major AT depots include 
subcutaneous (below the skin), visceral (around the organs), intrahepatic (Koska et al. 
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2008) and to a lesser extent bone marrow (yellow bone marrow) and breast tissue. Its 
main role is to store excess triglycerides which are esterified to free fatty acids and 
glycerol as well as function as an energy reserve, insulate the body and cushion vital 
organs. Additionally, AT acts as an endocrine organ (Kershaw, 2004) and has been 
shown to synthesize and secrete a number of hormones, called adipokines, which are 
involved in the regulation of energy homeostasis, insulin action, and lipid metabolism 
(Dyck et al. 2006). Some of the hormones considered to play key roles in energy 
metabolism, include leptin and adiponectin. When the body accumulates excessive AT it 
may lead to disruptions in endocrine signaling which can disrupt other organ systems of 
the body and may lead to disease (Galic et al. 2010).  
Leptin is secreted by white adipose tissue (WAT) (Zhang et al. 1994). Leptin is 
produced in proportion to body fat mass and can act on the brain to induce satiety and 
regulate AT mass (Ainslie et al. 2000). It has been suggested that the primary role of 
leptin is in adaptation to negative energy balance (Kiem et al. 1998). As such, leptin was 
originally proposed to act as a signal indicating abundant adipose stores to the 
hypothalamus to limit energy intake and increase energy expenditure (Campfield et al. 
1996). Accordingly, decreases in circulating leptin are associated with increased hunger 
(Kiem et al. 1998) and leptin replacement prevents the compensatory decrease in 
metabolic rate and thyroid function after diet-induced weight loss in humans (Faraj et al. 
2003). Furthermore, there is some evidence linking leptin to a direct regulation of AT 
metabolism through inhibition of lipogenesis and stimulation of lipolysis (Meier et al. 
2004).  
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Adiponectin is a protein hormone that modulates a number of metabolic 
processes, including glucose regulation and fatty acid oxidation (Diez et al. 2003). 
Adiponectin is exclusively secreted from AT and is one of the most abundant AT-specific 
factors (Fruhbeck et al. 2003). Data suggest that adiponectin is a mediator of insulin 
sensitivity and an enhancer of fatty acid oxidation (Berg et al. 2002). In contrast to leptin, 
plasma levels of adiponectin are lower in obese subjects, and the low levels are 
associated with increased risk factors for insulin resistance (Hotta et al. 2000). Low levels 
of adiponectin are also associated with the reduced ability of insulin to phosphorylate 
insulin receptor tyrosine residues and are therefore predictive of the development of 
insulin resistance in humans since tyrosine phosphorylation is essential to activation of 
the insulin signaling pathway (Faraj et al. 2003). Administration of adiponectin to rodents 
increases insulin sensitivity, an action that appears to result from lowered hepatic glucose 
production and increased muscle fatty acid oxidation. Moreover, adiponectin knockout 
mice exhibit insulin resistance (Kubota et al. 2002) and circulating adiponectin 
concentrations have been reported to increase after weight loss (Yang et al. 2001). 
 
2.4.2 Differentiating overweight and obesity 
Obesity or being overweight in humans and most animals does not depend on body 
weight alone, but rather on body composition, specifically the amount of AT that 
accumulates. A poor diet combined with physical inactivity is known to cause overweight 
and obesity. Obesity is an excessive accumulation of fat within the body, this 
accumulation results in an imbalance between energy intake and energy expenditure 
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(Cummings and Shwartz, 2003). In this case, the nutrient supply, particularly in the form 
of high fat foods, exceeds energy expenditure of the individual thus increasing body fat 
stores (Trembly et al. 1989). To determine whether accumulating adiposity results in an 
individual becoming overweight or obese is usually determined through measurements 
such as the body mass index (BMI), waist circumference, or waist-to-hip ratio (American 
Diabetes Association). The risk of secondary diseases increases with the severity of 
overweight. BMI is calculated from the size and weight and is only considered clinically 
relevant for persons 18 years and older. Categories of BMI include: 1) normal weight is a 
BMI between 19 to 24.9 kg / m2 for women and between 20 to 24.9 for men; 2) 
overweight is a BMI between 25 and 29.9 kg / m2; 3) obesity is considered a BMI above 
30 kg / m2 (CDC, 2004). 
 
2.4.3 Causes of increased adiposity 
Causes of increased adiposity can range from physical, psychological, and environmental 
factors such as: high-fat diet and sedentary lifestyle, depression, emotional eating, 
familial predisposition, lack of access to healthy food or safe places to walk/play, cultural 
ideologies regarding food, secondary to disease states (hypothyroidism, abnormal cortisol 
metabolism), as well as undetermined factors (CDC, 2004) .  
  
2.4.4 Pathophysiological consequences of increased adiposity  
Increased adiposity may lead to both adverse physical and/or metabolic consequences 
such as respiratory distress; dyspnea or respiratory arrest attacks during the night (sleep 
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apnea); overbearing joint and articular problems such as back or knee pain; cardiac 
disorders ranging up to infarction and heart failure after fat accumulation in the heart; 
arteriosclerosis; insulin resistance, pre-diabetes, type 2 diabetes; increased levels of blood 
lipids (cholesterol and triglycerides) (Poirie et al. 2006r); non-alcoholic hepatic steatosis; 
calcifications of the gallbladder and coronary artery (Aoqui et al. 2013); leg vein 
thrombosis (partial or complete obstruction of leg vein); damage to the joints 
(osteoarthritis); and complications during pregnancy . 
 
 
 
2.5 Progression from Increased Adiposity to T2D 
2.4.1 Pathogenesis of increased adiposity 
As stated earlier, obesity is characterized by an excess of body fat and is associated with 
a state of chronic, low-grade inflammation. The link between obesity and inflammation 
was first established by Hotamisligil et al, (1993) who showed a positive correlation 
between adipose mass and expression of the pro-inflammatory gene tumor necrosis 
factor-alpha (TNF-alpha) (Hotamisligil et al. 1993). The link between obesity and 
inflammation has been further illustrated by increased plasma concentrations of several 
pro-inflammatory markers including cytokines and acute phase proteins like C-reactive 
protein (CRP) in obese individuals (Trayhurn et al. 2005).  Adipocytes are associated 
with the production of pro and anti-inflammatory adipokines.  
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As a secretory organ, AT displays several unusual characteristics. First, the 
different fat depots (visceral vs. subcutaneous) are heterogeneous not only in terms of 
metabolic capacities, but also of adipokine secretion patterns (Guerre-Millo, 2004). 
Differences in where adipose is distributed may have a direct impact on secretion thus 
variations in local repercussions on the AT by autocrine or paracrine mechanisms. 
Second, AT is composed of distinct cell types: mature adipocytes and stromal-vascular 
cells (SVC, non-fat cells; including macrophages), all of which may contribute to the 
secretory functions and effects of AT (Guerre-Millo, 2004). 
Mature adipocytes represent 50–85% of the total cellular components of AT. The 
cellular composition of AT can vary according to anatomical location and body weight. 
In human obesity, AT is characterized by adipocyte hypertrophy (increased size) and 
hyperplasia (increased number), macrophage infiltration, endothelial cell activation and 
fibrosis (Faust et al. 1978, Henegar et al. 2008 and Maury et al. 2007). Increased fat 
storage in fully differentiated adipocytes, resulting in hypertrophy is thought to be the 
most important determinant whereby fat depots increase in adults (Spalding et al. 2008). 
With increasing AT accumulation, such as in the case of obesity, adipocytes undergo 
metabolic changes.  Additionally, adipocyte size is related to dysregulated adipokine 
expression and secretion in humans, wherein the hypertrophic adipocytes have altered 
intracellular signaling that shifts the balance towards the production of pro-inflammatory 
molecules (Jernas et al. 2006 and Skurk et al. 2007). These pro-inflammatory mediators 
include TNF-alpha, interleukin (IL)-6, IL-1beta, adiponectin, leptin, and resistin. WAT is 
also known to produce chemokines such as IL-8 and monocyte chemoattractant protein 
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(MCP)-1. Obese AT is characterized by macrophage infiltration and these macrophages 
are an important source of inflammation in this tissue as well as an elevated production of 
adipose-derived pro-inflammatory mediators (Suganami et al. 2005). 
TNF-alpha appears to be one of the most central pro-inflammatory mediators 
released by AT that contributes to and promotes obesity-associated inflammation. 
Adipose tissue and circulating levels of TNF-alpha are elevated in obese subjects and fall 
after weight loss (Dandona et al. 1998; Maury et al. 2009). TNF-alpha is also higher in 
visceral than subcutaneous fat, and more abundantly produced by macrophages that have 
infiltrated AT than adipocytes themselves (Fain et al. 2004; Maury et al. 2009). Most 
effects of TNF-alpha on AT are mediated by the TNF-alpha receptor 1 subtype (TNFR1) 
and subsequent activation of various transduction pathways (Cawthorn and Sethi, 2008). 
Two transcription factor-signaling pathways have been linked to the pro-inflammatory 
effects of obesity: the nuclear factor-kappa B (NF-kappa B) and c-Jun NH2-terminal 
kinase (JNK) pathways (Shoelson et al. 2007). Cell culture studies have supported this 
regulatory effect of TNF-alpha in obesity as demonstrated by an increase in constitutive 
NF-kappa B activity (Berg et al. 2004).  
Adipocytes in obese human subjects have additionally been shown to be hyper-
responsive to TNF-alpha which in turn functions to propagate inflammation by up-
regulating pro-inflammatory mediators such as IL-6 and MCP-1, both of which have 
been shown to be elevated in obesity (Bastard et al. 2006). In fact, adipose tissue may 
contribute up to 15–35% of the systemic IL-6 in humans (Mohamed-Ali et al. 1997). 
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Additionally, adipose-derived TNF-alpha acts to down-regulate anti-inflammatory 
adipokines such as adiponectin (Bruun et al. 2003, Maury et al. 2009).  
Two other biological pathways have been suggested in the relationship between 
obesity and activation of the immune system. The first pathway which could link obesity 
to altered production of adipokines is AT hypoxia (Trayhurn et al. 2008 and Ye, 2009). 
The causal link between hypoxia and changes in adipokine production has been 
confirmed in vitro and has been demonstrated in obese mice by several techniques 
(Hosogai et al. 2007 and Ye et al. 2007). In several models of cultured adipocytes, 
hypoxia decreased mRNA levels of adiponectin, while increasing those of pro-
inflammatory genes (plasminogen activator 1 (PAI-1), TNF-alpha, IL-1, IL-6, and MCP-
1,) together with those of hypoxia response genes (hypoxia inducible factor-1 alpha (HIF-
1 alpha), glucose transporter 1, vascular endothelial growth factor (VEGF)) (Hosogai et 
al. 2007, Wang et al. 2007 and Ye et al. 2007). The expression of inflammatory genes 
was also induced by hypoxia in cultured macrophages (Ye et al. 2007). The molecular 
mechanisms of dysregulated gene expression are related to activation of the transcription 
factors NF-kappa B and HIF-1 alpha, to endothelial stress and to post-transcriptional 
alterations (Hosogai et al. 2007 and Ye, 2009). Thus, hypoxia may underlie the 
development of the inflammatory response in AT, leading to obesity-associated diseases.  
Second, it has been suggested that a paracrine loop between adipocytes and 
macrophages establishes a vicious circle that aggravates the inflammatory changes in AT 
(Suganami & Ogawa, 2010). This paracrine loop involves free fatty acids (FFAs) and 
TNF-alpha. Enlarged adipocytes release excess saturated FAs that activate macrophages 
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via toll-like receptor 4 (TLR4) signaling (Suganami & Ogawa, 2010). TLRs play a 
critical role in the innate immune system by activating pro-inflammatory signaling 
pathways in response to microbial pathogens. The activation of TLR4 upregulates 
intracellular inflammatory pathways related to the induction of insulin resistance, such as 
JNK or NF-kappa B. TLR4 has been proposed to be a molecular link between lipids, 
inflammation and insulin resistance (Shi et al. 2006). Thus, TLR4-knockout mice are 
protected against lipid-induced inflammatory changes, insulin resistance and obesity (Shi 
et al. 2006 and Tsukumo et al. 2007). Additionally, TLR4 expression was increased in 
AT of obese mice (Shi et al. 2006). TLRs are also expressed in human AT (Vitseva et al. 
2008). As a result, macrophages secrete TNF-alpha, which in turn acts on TNFR1 to 
induce inflammatory changes in hypertrophic adipocytes through activation of the NF-
kappa B pathway and enhanced FFA release (Suganami & Ogawa, 2010). FFAs may also 
act on adipocytes in an autocrine fashion to generate inflammation and 
chemokine/adipokine overproduction at least in part via TLR4 (Jiao et al., 2008). 
Obesity is often associated with the pathogenesis of insulin resistance, MetS, and 
T2D. This link between obesity-induced dysfunction in adipocytes and its related co-
morbities appears to be increased in adipose tissue-mediated adipokines. In states of 
increasing adiposity the majority of adipokines with pro-inflammatory properties are 
overproduced while those adipokines with anti-inflammatory or insulin-sensitizing 
properties, like adiponectin are diminished. This dysregulation of adipokine production 
may promote obesity-linked metabolic disorders and cardiovascular disease.  
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2.6 Impaired Insulin-Mediated Vasodilation 
2.6.1 Insulin-mediated vasodilation and vascular health 
Insulin has important vascular actions to stimulate production of nitric oxide from the 
endothelium. This leads to capillary recruitment, vasodilation, increased blood flow, and 
subsequent augmentation of glucose disposal in classical insulin target tissues (e.g., 
skeletal muscle) (Muniyappa et al. 2007). The PI3K insulin-signaling pathway also 
regulates endothelial production of nitric oxide (NO). Insulin binding to its membrane-
bound receptor (IR) subsequently stimulates IRS-1/IRS-2 which activates PI3K leading 
to phosphorylation of protein kinase B (PKB/Akt) and phosphatidylinositol-dependent 
kinase 1(PDK-1) therefore stimulating endothelium nitric oxide synthase (eNOS) 
(Assunta Potenza et al. 2009). eNOS is an SH-dependent enzyme with a cysteine residue 
at its active site that is important in regulating vascular tone by catalyzing the production 
of NO from L-arginine (Figure 1; Chen et al. 1994, Vasdev et al. 2006). These and other 
cardiovascular actions of insulin contribute to the coupling of metabolic and 
hemodynamic homeostasis under healthy conditions. Cardiovascular diseases are the 
leading cause of morbidity and mortality in insulin-resistant individuals (ADA). 
Therefore, examination of markers of inflammation and oxidative stress that directly 
impact the vascular insulin signaling pathway may be relevant in evaluating the efficacy 
of specific therapeutic interventions aimed at ameliorating endothelial dysfunction. 
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Figure 1. Insulin-Mediated Vasodilation Pathway. 
 
2.6.2 Pathogenesis of Impaired Insulin-Mediated Vasodilation 
Increased adiposity is associated with the development of diabetes, hypertension, and 
cardiovascular disease. Oxidative stress is a complication of diets high in fat and 
increased adiposity and can directly induce hypertension through O2˙ˉ-mediated 
scavenging of the endogenous vasodilator NO (Dobrian et al. 2001, Taniyama et al. 
2003).  
Oxidative stress can occur as a result of decreased activity or expression of 
antioxidant enzymes with an increase in enzymatic generation of O2˙ˉ. Superoxide 
generation serves as a precursor for a number of reactive oxygen and nitrogen species. 
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Therefore oxidative stress results from an imbalance of reactive oxygen species (ROS) 
generation. Some major sources of ROS include uncoupling of the electron transport 
chain resulting in increases in NOS as well as by NADPH oxidases. Hyperglycemia and 
dyslipidemia also contribute to increased ROS production in addition to initiating insulin 
resistance through down-regulation of insulin signaling pathway intermediates 
(Newsholme et al. 2007). In addition to increases in oxidative stress, HFDs inhibit the 
vascular insulin signaling pathway. Since normal tyrosine-autophosphorylation of the 
insulin receptor (IR) is down-regulated in favor of serine/threonine phosphorylation, 
stimulation of intracellular signaling intermediates is impaired leading to downregulation 
of IRS-1, PI3K, PKB/Akt, and PDK-1 phosphorylation leading to further decreases in 
eNOS and NO production (Figure 2; Montagnani et al. 2002). Alterations to the cysteine 
residue of eNOS also results in loss of catalytic activity. Moreover, oxidation of the 
eNOS cofactor tetrahydrobiopterin causes the uncoupling of eNOS, resulting in 
decreased formation of NO and an increase in O2˙ˉ production (Thum et al. 2007, Xia et 
al, 1998). NO is not only a potent vasodilator, it also inhibits platelet aggregation, 
vascular smooth muscle cell (VSMC) migration and proliferation, monocyte adhesion, 
and adhesion molecule expression (Taddei et al. 2004). Decreasing NO bioavailability 
while at the same time producing excess ROS, therefore, leads to the endothelial 
dysfunction (Tian et al. 2012). Endothelial dysfunction, or impaired endothelium-
dependent vasodilation, is observed with insulin resistance, diabetes, obesity, and 
dyslipidemia is therefore a prominent component of hypertension, coronary heart disease, 
and atherosclerosis. 
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2.6.3 Oxidative Stress 
Proteins, lipids and DNA are cellular targets for oxidation, which lead to alterations in 
their structure and function. ROS can cause these alterations through oxidation of critical 
amino acid residues, such as cysteine residues as previously described for eNOS, which 
may alter enzyme activity or may affect transcriptional activities if they are within the 
binding site of transcription factors. Intra- or intermolecular conformational changes, 
such as the formation of disulfide bridges between or within proteins, may result in an 
alteration of protein activity or function. Metal-catalyzed oxidative reactions may cause 
modifications to membrane proteins and lipids, leading to degradation whereas 
peroxidation reactions may lead to degradation of membrane lipids with loss of 
membrane integrity, and release of aldehydes, possibly altering ion channel or receptor 
function. Finally, overstimulation of ROS-mediated signaling pathways may result in 
over-expression of inflammatory factors, increased vascular cell proliferation and 
apoptosis (Giordano et al. 2005, Vasdev et al. 2006). 
Numerous enzymes are involved in cellular regulatory functions, and oxidative 
modification of these enzymes may result in adverse effects contributing to the 
development and progression of hypertension and atherosclerosis. Antioxidants, which 
normally attenuate ROS-mediated damage, are often down-regulated in disease states. An 
important antioxidant pathway is the breakdown of O2˙ˉ by superoxide dismutase (SOD) 
to form hydrogen peroxide (H2O2), which is further converted by catalase or glutathione 
peroxidase to water and oxygen. Increases in the vascular levels of O2˙ˉ lead to 
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endothelial dysfunction through decreasing the bioavailability of NO. Animal and cell 
culture studies have demonstrated glutathione peroxidaxe (GPx) and glutathione 
reductase (GRed) are two additional key antioxidant enzymes that protect cells from 
oxidative damage. The enzymes themselves have been shown to be susceptible to 
modifications resulting from oxidation with loss of activity, resulting in perpetuation of 
oxidative stress (Cullen, 2010, Jones, 2006, Vasdev 2006). In both in vitro and in vivo 
studies of spontaneously hypertensive rats (SHRs) (models of human essential 
hypertension) there are increased ROS levels in vascular tissue, with a decrease in 
glutathionine (GSH) levels and antioxidant enzyme activity (Elmarakby and Imig, 2010, 
Dobrian et al. 2001).  
ROS act on yet another enzyme, angiotensin-converting enzyme (ACE), to 
increase catalytic activity, resulting in an increase in angiotensin II (AII) production 
(Takemori et al. 2007). AII is a potent vasoconstrictor implicated in the pathogenesis of 
hypertension and atherosclerosis. AII binds to its type 1 receptor, which results in an 
increase in contraction, hypertrophy, proliferation and apoptosis. AII stimulation of its 
type 1 receptor also increases the production of O2˙ˉ by the enzyme NADPH oxidase 
(Roberts et al. 2000). This enzyme is implicated as a major source of oxidative stress in 
cardiovascular disease. AII-induced oxidative stress (via NADPH oxidase) may be 
responsible, at least in part, for the decrease in NO bioavailability and the subsequent 
endothelial dysfunction found in hypertension and atherosclerosis. 
 
2.6.4 T2D, Obesity, and Vascular Dysfunction 
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A final link between adipokines, vascular dysfunction and cardiovascular disease 
involves the influence of perivascular adipokines, adipokines released from the 
immediate adipose tissue adjacent to the vasculature, on the vascular effects of insulin. 
Insulin normally induces vasodilation in muscle tissue to promote high glucose uptake 
and vasoconstriction in muscle tissue with low glucose uptake (Clark et al. 2003). This 
involves a delicate balance of the vasodilatory effects of NO and the vasoconstrictor 
effects of endothelin-1 (Blendea et al. 2003). This insulin-mediated blood flow is a major 
determinant of whole-body insulin resistance. In obesity, NO production is reduced 
whereas endothelin-1 production is increased along with reduced capillary recruitment 
(Sacks et al. 2007). Adipokines secreted by perivascular AT are believed to contribute to 
these changes that would work together to impair blood flow. For example, TNF-alpha 
has been shown to impair insulin-induced vasodilation (Enringa et al. 2007) possibly 
through reduced expression of IRS1. Adiponectin also influences insulin signaling, but in 
contrast to TNF-alpha and IL-6, is associated with increased sensitivity to insulin and 
increased glucose uptake (Hopkins et al. 2007). 
 
2.7 Diabetes and increased risk of cardiovascular disease 
Cardiovascular disease (CVD) in the US is the leading cause of mortality and accounts 
for 36% of all deaths. Furthermore, the economic burden of CVD was estimated as $475 
billion dollars in 2009 in both direct and indirect costs (AHA, 2010). Risk factors for 
CVD include both non-controllable factors such as age, gender, ethnicity, and genetics, as 
well as controllable factors such as diet, physical activity levels, weight, and smoking. 
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Other reversible risk factors include high blood pressure and unhealthy lipid profiles (low 
HDL, high LDL, high total cholesterol, and dyslipidemia). Additionally, other emerging 
independent factors such as hyperglycemia, postprandial lipidemia, hyperinsulinemia, 
oxidative stress, endothelial dysfunction, increased concentrations of inflammatory 
markers, and accumulating adipose tissue including perivascular adipose tissue have been 
suggested as contributing factors to the onset and progression of CVD (Cullen, 2000; 
Hackam and Anand, 2003; Pearson et al. 2003; Willerson and Ridker, 2004). With the 
US population currently experiencing a high rate of events including a large aging 
population, as well as an increased prevalence of obesity, metabolic syndrome, and T2D 
there is potential for a dramatic increase in the incidence of CVD. In fact, the AHA 
(2010) has estimated that in 2030 40.5% of the population within the US will develop 
CVD as compared to 37% of the population in 2010 resulting in an increase in the 
economic burden of CVD to $818 billion in direct costs and indirect costs of $276 billion. 
The risk of deaths of patients with type 2 diabetes from CVD-related events is 2 to 4 
times higher as compared to persons without diabetes (Buse, 2007).  Among white, non-
hispanic Americans, the age-adjusted prevalence of coronary heart disease (CHD) is 
twice as high among those with type 2 diabetes as among those without diabetes (Isomaa 
et al, 2001). These cardiovascular events associated with T2D as well as the high 
incidence of other macrovascular complications, such as strokes and amputations, further 
complicate the treatments and outcomes of illness and add to the already enormous 
economic burden of T2D. Multiple modifiable risk factors for late complications in 
patients with T2D, including hyperglycemia, hypertension, and dyslipidemia, increase the 
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risk of a poor outcome (Nandish et al, 2011). Recent guidelines from the ADA and other 
national organizations such as the AHA recommend a multifactorial approach to the 
management and treatment of diabetes and diabetes-related CVD risk factors.  
The NCEP ATP III and the AHA consider diet modification as a primary 
approach to prevent and treat hyperlipemia and hypertension. In 2010, the USDA 
released the 2010 “American Dietary Guidelines” (DGA) which emphasized healthy 
eating behaviors and physical activity aimed at reducing the prevalence of overweight 
and obesity and diet-related chronic disorders. AHA set forth nutritional guidelines aimed 
at preventing CVD and stroke or reducing associated risk factors. This guideline targeted 
5 major dietary intake factors including increasing daily fruit and vegetable intake, 
increasing consumption of fatty fish, reducing sodium as well as sugar-sweetened 
beverages, and increasing daily fiber intake. In a two-year follow-up, it was demonstrated 
that participants who followed the AHA nutritional guidelines did see significant 
improvements in measured lipid and cardiometabolic parameters (Redaelli et al. 2012)  
However, according to NHANES data, the prevalence of meeting all seven AHA health 
metrics at ideal levels was 1.2% in 2005-2010 (Shay et al, 2013). Moreover, only 20% of 
adults followed at least two dietary recommendations. Interestingly, in a recent study it 
was demonstrated that clinical trials that focused on only 1 of the 5 healthy eating factor 
goals, specifically fiber, resulted in a significantly greater adherence rate. Furthermore, 
those nutrition interventions that focused on daily fiber consumption had improvements 
in CVD risks (Post et al. 2012). 
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While it is agreed upon that meeting a greater number of healthy eating 
parameters in accordance with the AHA guidelines results in decreases in CVD mortality 
as evidenced by a 49% risk reduction in all-cause mortality in individuals who met all 
healthy eating factors (Ford et al.), only a minor percent of the population fits into this 
quintile as described previously. Therefore, finding simple dietary strategies, which have 
the potential to attenuate cardiometabolic risk factors, which are easy to adhere to and 
incorporate into a normal diet may prove to be tremendously beneficially to populations 
such as patients with T2D who are at increased risk.  
 
 
 
2.8 Nutrition interventions and dietary fibers 
2.8.1 Potential Use of Dietary Fibers in the Treatment of T2D 
Dietary fiber is defined as the portion of plants that is composed of complex carbohydrate 
polymers of simple sugars. Fibers can be classified as either soluble fiber or insoluble 
fiber. Soluble fibers, commonly referred to as viscous fiber, consist of gel-forming 
substances, such as pectin, gum, and mucilage that tend to be efficiently degraded by 
bacteria in the colon. Insoluble fibers, known as bulk fiber, consist of structural or matrix 
fiber such as, lignin, cellulose, and some hemicellulose that passes through the body 
unchanged (Gray, 1995; Hunt et al. 1993). The fibers used in this study, flaxseed (Linum 
usitatissimum) and psyllium (Plantago ovato) are both water-soluble fibers. Soluble 
fibers can function in nutrient metabolism in the body by delaying gastric emptying as 
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well as adsorbing or binding bile acids and products of fat digestion such as bile acids 
during passage through the intestines (Anderson et al. 1988; Hunt et al. 1993; Levin et al. 
1990). Epidemiological data suggests that dietary fibers may function to attenuate 
hyperglycemia (Anderson et al. 2009). Clinical trials have supported this association 
between dietary fiber intake and regulation of glucose homeostasis by demonstrating 
dietary fiber decreases post-prandial glucose and insulin responses in T2D patients 
(Anderson et al. 1999; Chandalia et al. 2000; Pastors et al. 1991; Rodrı́guez-Morán et al. 
1998). Additionally, clinical research has shown that fibers improved long-term glucose 
control in T2D (Giacco et al. 2000; Wolk et al. 1999). The benefits of a high-fiber diet on 
reducing glucose levels are still controversial (Nuttall et al. 1993) and have not been fully 
studied or appropriately tested in T2D as there are few controlled studies. Furthermore, 
the considerable amount of fiber used in these studies is controversial due to lack of 
adherence in a normal diet and adverse effects that are associated with sudden increases 
in fiber or long term very high fiber consumption such as gastrointestinal distress, 
disruption of the gut flora, and impaired mineral absorption (Beattie et al. 1988; Scott et 
al. 1988; Tattersal et al. 1990). Alternatively, the ADA recommends a fiber consumption 
of 25 g/d for women and 38 g/d for men, however, it is estimated that the average U.S. 
adult consumes only 15 g/d which is well below the recommended intake. There is 
general consensus that moderate amounts of fiber from a variety of plant-based food 
sources are a vital component of a healthy diet, thus most controversy regarding the 
effects of fiber in the regulation of glucose is not due to the effectiveness of the dietary 
approach but whether or not it is feasible.  
50 
 
 
2.8.2 Reported Benefits of Psyllium and glucose control 
Psyllium that is used for the majority of the world’s consumption is comprised of the 
mucilage portion of the psyllium plant obtained from the outer layer of the seed known as 
the seed coat. Mucilage yield amounts to about 25% (by weight) of the total seed yield. 
The mucilage is often referred to as husk, or ground psyllium husk. The ground husk 
mucilage is a white fibrous material that is hydrophilic, meaning that its molecular 
structure causes it to attract and bind to water. Upon absorbing water the mucilage can 
increase its volume up to ten-fold. Previous studies have demonstrated a beneficial effect 
of dietary psyllium-derived fiber for reducing cholesterol levels in patients with 
hypercholesterolemia (Anderson et al. 2000; Olson et al, 1997; Sprecher et al. 1993) 
whereas the effect on glucose serum levels of a diet supplemented with soluble fibers 
varies according the dose consumed (Chandalia et al. 2000; Weickert et al. 2008). In 
studies examining the dosage amount of psyllium required to elicit a change in glucose-
related outcomes has demonstrated that there is little change in measured variables using 
lower quantities of Psyllium (7 g/d) ( Rodrı́guez-Morán et al. 1998). However, when the 
dose is increased up to 20 g/d there was a significant reduction in both basal and 
postprandial hyperglycemia (Abraham et al. 1988; Anderson et al. 2000; Jenkins, 2002; 
Pereira et al. 2001). 
 
2.8.3 Nutrient Composition of Flaxseeds 
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Flaxseed is a food that is commonly consumed as whole seed, ground seed (powder or 
meal), or in its oil form. The nutritional composition varies between the three forms of 
flaxseed (refer to Table 1) as flaxseed oil is devoid of any fiber and lignan components 
but is unique as it contains high percentage by weight of both monounsaturated fatty 
acids (18%) as well as polyunsaturated fatty acids (73%) and is the richest food source of 
alpha lineoleic acid (ALA, 55%). Studies conducted on the bioavailability of ALA in 
flaxseed after consumption indicates that both flax oil and ground flaxseed provide 
significant levels of ALA after digestion, however, whole flaxseed did not (Katare et al. 
2012). The whole seed and ground meal forms contain both insoluble and soluble fibers. 
The soluble fiber content of flaxseeds is derived from the mucilage portion of the seed 
and contributes to approximately 25% of the total dietary fiber of flaxseeds. Previous 
research in both animal models as well as clinical trials has demonstrated that this soluble 
fiber component may explain the cardioprotective effects attributed to flaxseeds (Carter 
et al. 1993; Kritchevsky et al. 1995; Wolever et al. 1995). In addition to high 
concentrations of the omega-3 fatty acid ALA and soluble fibers, flaxseeds are also a 
good source of multiple micronutrients associated with vascular health including vitamin 
E as gamma-tocepherol and the B vitamins (thiamin (B1), riboflavin (B2), niacin (B3), and 
pyridoxine (B6)). Flaxseeds also contain high concentrations of folate, potassium, 
phosphorous, magnesium, and zinc, however, due to the presence of phytic acid and 
oxalate which act as chelators and bind magnesium and zinc to form insoluble complexes 
in the intestine (Robson, 2009), the bioavailable amounts of these minerals is relatively 
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low. It is worth noting that some studies of animal models indicate that phytic acid 
independently lowers blood glucose levels (Lee et al. 2006).  
 
 
Table 1. Comparison of the Nutrient Composition of Flaxseed Forms 
Flaxseed 
Form 
Weight 
(g) 
Energy 
(Kcals) 
Total fat 
(g) 
Total 
ALA (g) 
Total fiber 
(g) 
SDG content 
(mg)a 
Whole 41.2 220 17.37 11.84 11.2 33.4 
Ground 28 150 11.8 8.04 7.6 24.32 
Oil 54.4 481 50.4 39.1 0.0 0.0 
Source: NDSR, 2012 
a secoisolariciresinol diglucoside 
 
2.8.4 Flaxseed-derived lignans and potential antioxidant properties 
Flaxseeds also contain a large concentration of phytoestrogen lignans. Plant lignans are 
phenolic compounds which are a class of chemical compounds consisting of 
a hydroxyl group (-OH) bonded directly to an aromatic hydrocarbon group. Plant lignans 
are found in a variety of commonly consumed foods and are considered naturally 
occurring phenolics. After ingestion they are metabolized via the xenobiotic pathway 
which is also the pathway responsible for drug metabolism. The carbohydrate portion is 
removed by intestinal bacteria to form the bioactive mammalian lignans: enterodiol and 
enterolactone (Bloedon et al. 2004). These mammalian lignans are then absorbed in the 
small intestine and conjugated in the liver. Conjugated lignans are then excreted from the 
body through urine and bile in addition to undergoing enterohepatic circulation which 
promotes reabsorption. Flaxseeds are the richest source of the lignan precursor 
secoisolariciresinol diglucoside (SDG) in addition to also containing minor lignan 
components isolariciresinol, pinoresinol, and matairesinol (Hutchchins et al. 2001; 
Meagher et al. 1999). Flaxseed consumption has demonstrated a linear, dose-dependent 
53 
 
relationship with urinary excretion of enterodiol, enterolactone, and total lignans in 
clinical trials (Morton et al. 1995). Prasad (1999) demonstrated that SDG, isolated from 
flaxseeds, lowered serum total cholesterol and LDL cholesterol and reduces 
hypercholesterolemic atherosclerosis in rabbits.  
Recent clinical trials have demonstrated flaxseed-derived lignans have serum 
cholesterol and glucose lowering effects in hypercholesterolemic subjects (Bloedon et al. 
2008; Pan et al. 2007; Zhang et al. 2008). Additionally, lignans, such as SDG, and its 
mammalian metabolites secoisolariciresinol, enterodiol, and enterolactone have 
demonstrated antioxidant activities (Prasad, 2000; Prasad, 1997). Studies exploring the 
effects of flaxseed-derived lignans have established antioxidant activity in vivo and in 
vitro resulting in increased total antioxidant capacity as well as decreased lipid 
peroxidation (Hu et al. 2007; Kitts et al. 1999; Niemeyer and Metzler, 2003). However, 
whole flaxseed had no significant effect on markers of lipid peroxidation in humans 
(Cunnane et al. 1995; Cunnane et al. 1993), but partially defatted flaxseed lowered serum 
protein thiol groups, indicating increased oxidation (Jenkins et al. 1999). The antioxidant 
activity of secoisolariciresinol and enterodiol found in flaxseeds is higher than that of 
vitamin E or the parent glucoside present in flaxseed (Prasad, 2000). As described earlier, 
oxidative stress has been shown to be a major contributor to the onset and progression of 
insulin resistance and T2D. Interestingly, SDG also reduces the incidence of diabetes in 
streptozotocin-induced diabetic rats (Prasad et al. 2000) and Zucker rats, a model for type 
2 diabetes (Prasad, 2001). 
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2.8.5 Flaxseeds-derived omega 3, T2D and CVD risks 
As previously stated (see Table 1), flaxseeds are a rich source of ALA. ALA is an 
essential omega-3 fatty acid which cannot be synthesized in the human body though can 
be converted (in variable amount) into the longer chain omega 3 fatty acids 
eicosapentaenoic acis (EPA) and docosahexanoic acid (DHA) (Burdge, 2004). The 
majority of research regarding potential benefits of flaxseed consumption is focused on 
markers of cardiovascular disease. While results are still inconclusive, recent data 
suggests that consumption of flaxseeds in all forms is associated with attenuated CVD 
risks. Potential mechanism by which flaxseeds may exert this protective effect include 
reduction of inflammation and oxidative stress as well as reducing total serum 
cholesterol, improving serum lipids, decreasing platelet aggregation, and attenuating 
vasoconstriction. These effects are primarily attributed to the large concentration of ALA 
as well as phytoestrogen lignans and the soluble fiber content of flaxseeds as previously 
discussed. Research regarding flaxseed consumption in animal models has primarily 
focused on the effects of flaxseed lignans in improvement of serum lipids (as discussed 
in2.7.2). However, when weanling female Wistar rats were fed diets supplemented with 
200 g/kg flaxseed for 4 weeks as compared to rats supplemented with ALA or diets high 
in saturated fatty acids, the flaxseed group demonstrated significantly decreased oxidative 
stress levels in response to the administration of a oxidative stress inducer, CCL4 
(MacDonald-Wicks and Garg, 2002).  
Epidemiological data on flaxseed consumption and risk of clinical studies 
observing the use of flaxseed oil have demonstrated that ground flaxseed intake can result 
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in modestly reduced total cholesterol and LDL-C concentrations without significantly 
decreasing HDL-C (Albert et al., 2005; Hu et al. 2004). Eleven major studies (Mantzioris 
et al, 1994; Allman et al. 1995; Caughey et al. 1996; Gibson et al. 2000; James et al. 
2000; Nordstrom et al. 1995; Nestel et al. 1997; Cunnane et al. 1993; Loria et al. 1993; 
Guan et al, 1998; Paschos et al. 2007; Ueshima et al. 2007) have reported that flaxseed-
derived ALA levels are inversely correlated with primary cardiovascular events. The 
results are from large sample populations or collected over multiple years. More evidence 
that dietary ALA has significant cardioprotective benefits has been demonstrated in 
secondary prevention trials. Studies such as the Nurses' Health Study (Hu et al. 1994) 
found that the intake of ALA in the diet protected against fatal ischemic heart disease and 
that this protection probably resulted from an antiarrhythmic effect of ALA. However, 
the protective effect of ALA did not extend to nonfatal myocardial infarction, for which 
there was a nonsignificant trend for an effect. Although there may be a direct effect on 
cardiac arrhythmias from dietary ALA, it is likely that its effect was mediated, in part, 
through the syntheses of EPA and DHA. In the Lyon Diet Heart Study (Axelson et al. 
1982), ALA was associated with a decreased risk of recurrent fatal and nonfatal 
myocardial infarction, and a 73% reduction in risk of primary end points (cardiac 
mortality and morbidity) between the experimental and control groups. In a double-
blinded, placebo-controlled study (Shakir et al. 2007) conducted in India, 120 patients 
with suspected acute myocardial infarction were followed and supplemented with 2.9 
g/day of ALA (enriched oil). After one year of follow-up, both cardiac death and nonfatal 
myocardial infarction were significantly lower in this group of patients compared with 
56 
 
those on placebo. Animal models exploring the relationship of flaxseed and CVD have 
demonstrated that flaxseed (0.4 g/day) effectively inhibited the expression of 
inflammatory markers such as interleukin (IL)-6, vascular cell adhesion molecule 
(VCAM)-1 in aortic atherosclerotic tissue from LDL receptor-deficient mice (Cunnane et 
al. 1995). It was concluded that an important antiatherogenic role of ALA may involve a 
potent anti-inflammatory action. These results have further been demonstrated in clinical 
trials. Two clinical trials with healthy subject populations have observed significant 
reductions of TNF-α, IL-1-beta, thromboxane B5 and prostaglandin E5 after 
administration of an ALA-rich diet (13.7 g/day of ALA from flaxseed) (Austria et al. 
2008). Additionally, in response to 2 g/d of flaxseed-derived ALA, expression of VCAM-
1 and E-selectin were significantly decreased (Bloeden et al, 2008). ALA intake (8 g/day) 
from a flaxseed source decreases serum concentrations of serum amyloid A and IL-6 
(Alonso et al. 1995). Additionally, Nestel et al (1997) reported that in obese human 
subjects, 20 g/day of ALA from flaxseed oil significantly increased arterial compliance 
and decreased LDL-C oxidation when it was compared with an oleic acid and saturated 
fat intervention. 
Flaxseed consumption may improve glucose regulation. Studies in animal models 
of diabetes mellitus have shown that SDG from flaxseed can prevent the development of 
type 1 diabetes by approximately 71% (Prasad, 2000) and T2D by 80% (Prasad, 2001). 
Pan et al (2007) reported more modest but statistically significant improvements in 
glycemic control in type 2 diabetic patients treated for 12 weeks with 360 mg/day of 
flaxseed-derived lignan supplement. Ingestion of flaxseed or ALA may help in 
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preventing or treating a variety of diabetic complications. Bloedon et al (2008) 
demonstrated that 40 g/d of ground flaxseed significantly improved insulin sensitivity in 
individuals with elevated LDL-C concentrations. Furthermore, studies in type 2 diabetic 
patients, 5 g/day of flaxseed oil consumption has been associated with a significant 
reduction of plasmin alpha-2-plasmin inhibitor complex level, plasminogen activator 
inhibitor-1 activity and thrombin antithrombin III complex level after a two week of 
intervention (Toghi et al. 2004). In an animal model, Velasquez et al (2003) reported that 
flaxseed meals reduced proteinuria and ameliorated nephropathy in type 2 diabetes 
mellitus. Due to the strong association between obesity and T2D, caution should be 
exercised in recommendations for a potentially high fat diet. Studies examining the 
effects of flaxseed consumption on changes in body mass have not found evidence that 
flaxseed induces weight gain or increases in body fat (Faintuch et al. 2007; Nelson et al. 
2007). 
2.9 Consequences or Implications 
The overall goal of this study is to contribute to the understanding of how flaxseed 
supplementation may help manage hyperglycemia in diabetes as well as improve vascular 
health. The results of this study will provide new insight into the feasibility of use 
regarding a plant-based dietary treatment for T2D that is predicted to have few, if any, 
side-effects and is affordable (as compared to oral hypoglycemic medications) which 
would also help to alleviate the economic burden of diabetes for many individuals from 
low socioeconomic backgrounds. Additionally, the findings of this study regarding the 
use of dietary interventions to reduce inflammation and oxidative stress which are similar 
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underlying factors of T2D, endothelial dysfunction, and cardiovascular disease will be 
applied to future work regarding the effects of diabetes on vascular health and the use of 
nutritional intervention therapy in an effort to further our understanding of the 
devastating effects of poor dietary habits and obesity on vascular health. The potential 
benefits of this study will be to establish and characterize how flaxseed supplementation 
may attenuate hyperglycemia and increased cardiovascular risks in non-insulin dependent 
diabetes patients and design future goals for implementing interventions with the aim of 
avoiding the adverse consequences of impaired insulin regulation, hyperglycemia and 
subsequent disease and help to establish optimal health.  
 
 
 
 
CHAPTER 3 
MATERIALS AND METHODS 
3.1 Study Design 
In this comparative single-blinded randomized double-arm parallel efficacy parallel trial, 
participants were randomly assigned to supplementation for eight weeks with 28 g/d of 
ground flaxseed (intervention) or the control, 9 g/d of ground psyllium husks, which was 
standardized to control for fiber content (Table 2). Furthermore, this was designed to be a 
pilot study to determine the following: 1) would participants adhere to the previously 
stated volumes of test foods supplemental to their normal diet for an eight week trial 
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period; 2) would test food volumes be adequate to elicit a detectable change in the 
measured variables; 3) would the trial length be long enough in order to elicit previously 
observed effects of either ground flaxseed supplementation or psyllium supplementation 
on measured outcomes including glucose regulation, lipid profiles, circulating 
inflammation concentrations, and markers of oxidative stress. Participants were asked to 
refrain from making any additional changes to their usual diet or activity levels 
throughout the duration of the entire study. The study was approved by Arizona State 
University’s Institutional Review Board (Appendix A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control Group: Ground psyllium husk (9 g daily) 
One-week pre-
trial 
• Consent  
• Medical 
History 
Questionnaire 
• Blood pressure 
• HbA1c testing  
• Body 
composition 
• Waist 
circumference 
• 3-day diet 
record 
instruction 
• Scheduled for 
initial fasting 
blood draw  
Baseline 
Start of trial 
• Stratify and 
random 
assignment 
• Blood Pressure 
• Fasting blood 
sample 
• Body 
composition 
• Waist 
circumference 
• 3-day diet record 
• Test food pickup 
• Return 3-day 
food records 
• Receive 
compliance 
calendar 
• Instructions for 
storage and 
consumption 
• Incentive ($20) 
 
 
Email communications to follow-up, answer questions, provide 
instructions  
 
Week 8 
Trial Completion 
• Blood pressure  
• A1c testing 
• Fasting blood sample 
• Body composition 
• Waist circumference 
• Return 3-day diet record 
and compliance calendar 
• Incentive ($20) 
Flaxseed Group: (28 g daily) 
March 2014 start of initial 
recruitment  
December 2014 
Recruitment ends 
February 2015 
Trial ends 
Assays and 
Analysis begin 
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Figure 2.  Study Timeline and Milestones for Eligible Participants.   
 
3.2 Participants and Recruitment 
3.2.1 Participants 
Participants for this study included 17 adults (18 - 75y) who had a medical diagnosis of 
non-insulin dependent type 2 diabetes mellitus at least 6 months prior to enrollment. 
Subjects were recruited from the Phoenix Metropolitan area through flyers (Appendix B), 
diabetes support groups and events, health fairs, local hospitals, clinics and doctor’s 
offices.  
 
3.2.2. Initial Screening 
Subjects were pre-screened by completing an online questionnaire (SurveyMonkey.com) 
(Appendix C) designed to assess the exclusion criteria. 
 
3.2.3 Exclusion Criteria 
Exclusion criteria included: history of flaxseed allergies, current fiber supplement use, 
insulin use, currently pregnant or planning to become pregnant, currently breastfeeding, 
active disease states (other than diabetes), and anticipated changes to diet or physical 
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activity levels. Prescription medication use by participants, including oral hypoglycemic 
agents, statins, and hypertensive medications were required to have been consistent prior 
to the trial and were to remain consistent throughout the study. 
 
3.2.4 Rolling Enrollment  
Participants were enrolled after successful completion of initial online survey. Participant 
inclusion into the 8 week trial was based upon a rolling recruitment. Enrollment began on 
March 2014 and was concluded on December 2014.  
 
 
 
3.2.5 Consent Visit 
A total of 66 potential participants responded to the online questionnaire (Fig. 3). Those 
subjects who passed the pre-screening stage were invited for an initial visit at the School 
of Nutrition and Health Promotion (SNHP) Research Facility in the Arizona Biomedical 
Collaborative Building (Phoenix, AZ). Informed consent was obtained during this visit 
(Appendix D and E) and each subject completed a medical history questionnaire 
(Appendix F). Following consent, glycated hemoglobin (HbA1c) was determined using a 
small blood sample collected by fingerprick (DCA Vantage autoanalyzer, Siemens, 
Washington, D.C.). Additionally, anthropomorphic measurements were recorded as 
described later (refer to 3.5.1).  
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66 potential participants completed online survey 
37 participants screened 
19 respondents reported 
no diagnosis of T2D 
 
3 respondents did not meet 
age criteria (18-75 y) 
1 respondent currently 
breastfeeding or 
pregnant
1 respondent not willing to 
travel 
4 respondents currently on 
insulin 
1 respondent started taking 
insulin prior to consent 
 
16 respondents did not reply 
to acceptance notice 
20 participants consented 
Flax n=9 Control n=8 
1 participant had 
adverse response to 
blood draw 
Figure 3.  Study CONSORT flow diagram. 
2 participants lost to 
follow-up (1 flax, 1 
control) 
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3.3 Treatment and Control Foods 
The test foods consisted of ground flaxseed (Midwestern Flax, Valley City, ND) and 
ground psyllium husks (NOW Foods, Bloomindale, IL). Test foods were measured by 
weight and packaged in individual serving food grade plastic bags (American Plastics, 
Tracy, CA) in the Nutrition Metabolic Kitchen, located in the Arizona Biomedical 
Collaborative Building. Participants received 56 individually packaged servings for each 
day of the 8 week study intervention period. Subjects were given instructions on proper 
storage as well as suggestions on how to incorporate the fiber supplements into their daily 
diets (Appendix G). Participants were instructed to consume one individual package per 
day and asked to consume the supplement every day of the week and at minimum 5 days 
of the week. Furthermore, subjects were allowed to distribute the fiber supplement 
throughout the day as they wished in an effort to improve compliance. The selected dose 
of the treatment fiber, ground flaxseed (28 g/d) is equivalent to approximately one quarter 
of a cup. Ground psyllium husks was chosen for the control intervention due to its 
common use as a dietary fiber bulking agent in addition to its reported cholesterol and 
glucose lowering effects (Ziai et al. 2005). Psyllium has demonstrated outcome 
improvements are linearly related to the consumed dose and in clinical trials relatively 
low doses of psyllium without dietary instructions (< 9 g/d) are not significantly observed 
with improvements in glucose regulation (Anderson et al. 1999; Theuwissen and 
Mensink, 2008; Ziai et al. 2005). The amount of ground psyllium (9 g/d) used for the 
intervention is equivalent to approximately 1.5 teaspoons and was standardized according 
to fiber to ensure equal fiber content in both test food variables (Table 2). To monitor 
compliance and whether participants maintained their usual dietary habits, participants 
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were asked to complete a 3-day food record (Appendix H) 3 days prior to their first 
fasting blood draw and again 3 days prior to their final fasting blood draw. In addition, 
they were given calendars which corresponded to the intervention period and asked to 
check off the day the supplements were consumed (Appendix I). The 3-day food records 
were reviewed and analyzed using Food Processor software (Esha Research, Salem, OR). 
Dietary variables of interest were estimates of total energy intake, percentage of energy 
provided by macronutrients (carbohydrate, fat, and protein), and total fiber consumed by 
the participants.  
Table 2. Nutrient Comparison of Test Foods 
Nutrient Ground Flaxseed (28g) Psyllium (9g) 
Total Energy (Kcals) 150 34 
Total Fat (g) 11.8 0.0 
Total ALA (g) 8.04 0.0 
Total carbohydrates (g) 8.09 8.0 
Total fiber (g) 7.6 7.0 
Soluble fiber (g) 
Total protein (g) 
2.8 
5 
7.0 
0.0 
Thiamin (B1) (mg) 0.46 0.0 
Riboflavin (B2) (mg) 0.045 0.0 
Niacin (B3) (mg) 0.862 0.0 
Vitamin B6 (mg) 0.132 0.0 
Folate (DFE) 24.0 0.0 
Calcium (mg) 71.0 30.0 
Magnesium (mg) 9.63 0.0 
Phosphorous (mg) 1079.0 0.0 
Potassium (mg) 1366.0 0.0 
Zinc (mg) 1.2 0.0 
SDG content (mg)a 24.32 0.0 
Source: NDSR, 2012 
a SDG, Secoisolariciresinol digluscside 
 
3.4 Blood Collection  
Fasting blood samples were collected at the beginning and end of the 8 week dietary 
intervention period. Fasting blood draws occurred in the morning between 7:00 am and 
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10:00 am at both time points. Participants were asked to fast for 10-12 hours prior to their 
fasting blood draws at the SNHP research facilities For each fasting visit, blood was 
collected from a routine venous puncture procedure using a 23-gauge butterfly venous 
puncture needle. If a venous blood draw was not possible from the antecubital vein in 
either arm, blood was collected from a vein in the subject’s non-dominant hand. Blood 
was collected into vacutainer tubes as follows: one separating tube containing serum-
clotting factor (7 ml), one tube containing EDTA for plasma (10 ml), and one potassium 
oxalate and sodium fluoride containing vacutainer tube for plasma (4 ml). Blood was 
immediately centrifuged at 10,000 x g at 4°C for 20 minutes, and serum/plasma was 
separated, aliquoted, and stored at -80°C for future analyses.  
 
3.5 Measurements 
3.5.1 Anthropometric Data 
Subject blood pressure was taken at one time-point during each visit prior to any 
additional measurements from the non-dominant arm (unless contraindicated) following a 
5 to 10 minute seated rest period (both feet resting on floor) using a Medline MDS2001 
automated blood pressure monitor (Medline Industries, Inc., Mundelein, IL). Height was 
measured in centimeters using a wall-mounted stadiometer. Body weight (in kilograms), 
percent body fat, and body mass index (BMI, kg/m2) were measured using a calibrated 
Tanita body composition analyzer (model TBF- 300A, Tanita Corporation, Tokyo, 
Japan). Waist circumference (in centimeters) was measured in inches using a flexible 
tape measure at the naturally smallest point of the natural waist, between the lowest rib 
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and the iliac crest. All measurements were performed at a single time point by the same 
study investigator to increase reliability and validity. 
 
3.5.2 Glucose and Lipids  
Fasting glucose concentrations were measured using an automated chemistry analyzer 
(COBAS C111 chemistry analyzer, Roche Diagnostics, Indianapolis, IN). Glucose was 
measured in plasma which was collected into a vacutainer tube containing potassium 
oxalate and sodium fluoride to prevent glycolysis. Measurements of lipids which 
included total cholesterol, low density lipoprotein cholesterol (LDL-C), high density 
lipoprotein cholesterol (HDL-C), and total triglycerides, were measured in serum and 
determined enzymatically on a COBAS autoanalyzer (COBAS C111 chemistry analyzer, 
Roche Diagnostics, Indianapolis, IN).  Very low density lipoprotein (VLDL)-cholesterol 
was calculated as total triglycerides/5.  
 
3.5.3 Fasting Insulin and HOMA-IR 
Insulin was measured in serum using a commercially available kit, ultra-sensitive human 
insulin radioimmunoassay kit (Cat. No. HI-14K; EMD Millipore, Billerica, MA). To 
determine insulin sensitivity, the homeostatic model assessment of insulin resistance 
(HOMA-IR) was calculated from fasting glucose and insulin values as follows: [fasting 
glucose (mg/dL) x fasting insulin (mg/dL)]/405. The calculated HOMA-IR value is 
highly correlated with the euglycemic clamp method (r2=0.88) (Matthews et al. 1985). 
Higher levels of HOMA-IR indicate diminished insulin sensitivity.  
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3.5.5 Markers of Inflammation and Oxidative Stress 
Increases in inflammatory markers, such as TNF-alpha, and reactive oxygen species 
(ROS) favor oxidative stress. Additionally, total nitrate and nitrite concentrations (i.e. 
NOx) are often utilized as a clinical marker for ROS generation and vascular dysfunction. 
TNF-alpha was measured in plasma using a commercially available ELISA kit (Cat. No. 
EH3TNFA; Life Technologies, Thermo Scientific, Waltham, MA) and measured at 450 
nm on a Multiskan GO microplate spectrophotometer reader (Thermo Scientific, 
Waltham, MA). Lipid peroxidation, a marker of oxidative stress, was measured using a 
commercially available thiobarbituric acid reactive substances (TBARS) assay kit (Cat. 
No. 0801192; Zeptometrix, Buffalo, NY) using a miniaturized version of the standard 
protocol (Appendix J) based on the reaction between malondialdehyde (MDA) and 
thiobarbituric acid (TBA). Absorbance was measured spectrophotometrically at 532 nm 
on a microplate absorbance reader (iMark plate reader; BioRad, Hercules, CA). Plasma 
levels of TBARS are expressed as nM MDA/L. Additionally, plasma concentrations of 
NOx were measured in EDTA plasma with a commercially available Greiss assay kit 
(Cat. No. 780001; Cayman, Ann Arbor, MI) according to the manufacturer’s protocol. 
Total plasma NOx activity was measured at wavelengths 450 nm and 550 nm (Multiskan 
Go; Thermo Scientific, Waltham, MA). Measurements at 550 nm were subtracted from 
measurements taken at 450 nm to correct for imperfections in the microplate.  Plasma 
concentrations of NOx are expressed in nM/L.  
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3.6 Sample Size Calculation 
This was designed to be a pilot study to determine the following: 1) would participants 
adhere to the previously stated volumes of test foods supplemental to their normal diet for 
an eight week trial period; 2) would test food volumes be adequate to elicit a detectable 
change in the measured variables, and 3; would the trial length be long enough to observe 
significant changes in previously described endpoint measurements. The primary 
endpoints were absolute change from baseline to week 8 in HbA1c (%) and plasma 
glucose. Secondary endpoints included: absolute changes in BMI (kg/m2), waist 
circumference, body fat %, fasting insulin, HOMA-IR, serum triglycerides, total 
cholesterol, HDL-C, measured LDL-C, calculated VLDL-C, plasma oxLDL (i.e. 
TBARS), serum TNF-alpha, and total plasma NOx. As previously stated, this study was a 
pilot trial in order to assess feasibility and generate data for future large scale clinical 
interventions. Conducting a pilot trial before a main study may potentially help to avoid 
erroneous main trials due to flaws in the study design and may increase the likelihood the 
main study will succeed. A modified power analysis for feasibility and pilot studies was 
performed to determine the sample size necessary to detect significant changes in the 
primary endpoints. 
Based upon published data (Hutchins et al. 2013; Mani et al. 2011), it was 
determined that a total of 50 participants would be needed to provide at least 80% power 
(at a significance level of 0.05) to observe an estimated 19.7% reduction in plasma 
glucose and 15.6% reduction in HbA1c for a large scale study design. This sample size 
was modified based upon recommendations proposed by Stallard (2012) and Chow 
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(2011) who collectively proposed that an appropriate sample size could be achieved by 
acquiring 8 to 15 participants per sample group to sufficiently mirror a large clinical trial 
with similar endpoints. A sample size of 16 total participants (8 per sample group) was 
constructed upon these recommendations. To account for an expected 20% attrition rate 
at follow-up additional participants were recruited (Fig. 4).  
 
3.7 Statistical Analyses 
Data was analyzed using SPSS 22.0 (IBM, 2014, Chicago, IL). Differences in baseline 
measurements between the flaxseed treatment group and the control group were 
determined using a student independent samples t-test. Between group changes from 
baseline to week 8 were determined by analyzing the absolute net change (week 8 values 
minus baseline values, Δ) with Mann Whitney U non-parametric analyses. Results are 
expressed as means ± standard deviation (SD). Results were considered significant at 
95% or above (p-value of ≤0.05). 
CHAPTER 4 
RESULTS 
 
4.1 Baseline Participant Characteristics and Dietary Intake 
Seventeen of the 20 enrolled participants (85%) completed all study related visits (Figure 
3). Baseline characteristics of the enrolled subjects are presented in Table 3. There were 
no significant differences in baseline measurements between the flaxseed and control 
groups (p>0.05). The mean age of participants in this study was 59.1 ± 7.8 years of age. 
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Additionally, the mean BMI (kg/m2) of the participants was 30.4 ± 5.8 and mean percent 
body fat was 34.9 ± 8.9%. Mean waist circumference (cm) for study participants was 
102.6 ± 16.4, both mean baseline measurements for waist circumference in women (98.6 
± 16.8 cm) and men (106.4 ± 16.0 cm) participants in this study were above the 
recommended healthy ranges for their respective gender (88 cm for women and 100 cm 
for men). Additionally, mean systolic blood pressure for participants (141.4 ± 13.9 mm 
Hg) fell within the American Heart Association’s diagnostic criteria for hypertension 
stage 1 (140-159 mm Hg) while the mean diastolic blood pressure of 77.1 ± 5.6 mm Hg 
was within the normal range (< 80 mm Hg). Finally mean baseline glycated hemoglobin 
(HbA1c) was 6.91 ± 1.7% which is considered within the diagnostic criteria for diabetes 
(> 6.5%).  
 
 
 
 
 
 
Table 3. Baseline Characteristics and Measurements for Study Participants 
Subject Characteristics Flaxseed (n=9) Control (n=8) p-valuea 
Age (mean ±SD), y 59.7±7.9 58.5±9.4 0.802 
Male sex, n  5 4 N/A 
Female sex, n  4 4 N/A 
Race/Ethnicity    
  White, n (%) 8 7  
  Non-Hispanic, n (%) 7 5  
  Black, n (%) 1 0  
  Asian, n (%) 0 1  
  Other, n (%) 0 0  
BMI (mean±SD), kg/m2 31.7±4.2 29.03±6.7 0.335 
Body Mass (mean±SD), kg 94.3±15.2 85.88±21.1 0.358 
Waist Circumference (mean ±SD), 
cm 
105.0±12.7 100.0±20.3 0.548 
HbA1c (mean ±SD), % 7.1±1.5 6.7±2.0 0.333 
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Body Fat (mean±SD), % 36.4±3.2 33.3±2.9 0.483 
Systolic BP (mean±SD), mm Hg 141.8±14.4 141.0±14.0 0.912 
Diastolic BP (mean±SD), mm Hg 76.1±4.0 78.3±7.1 0.448 
Current Smokers, n (%) 0 0 N/A 
a Between group baseline measurements were analyzed using Student’s Independent samples t-test. 
Significance was set at α < 0.05.  
Abbreviations: HbA1c-glycated hemoglobin; BMI- body mass index; BP-blood pressure 
 
 
4.2 Nutrient Intake 
 
Analysis of nutrient intake from 3-day food records completed by all subjects the 3 days 
prior to baseline fasting blood draw and the 3 days prior to week 8 fasting blood draw 
showed no significant differences in nutrient intake between groups at baseline or at 8 
weeks (Table 4). Prior to the start of the nutrition intervention, participants were given 
compliance calendars to keep a tally of the days test foods were consumed. Based upon 
compliance records returned by 16 of the 17 participants, compliance with the study 
protocol was very high (92.8 ± 8 %). Additionally, there were no reported differences in 
adherence between the flaxseed (92.3 ± 10%) and control groups (93.3 ± 6%) during the 
8 week trial period. Data on compliance was missing in 1 subject (control group) which 
was not included in the subject adherence analysis.  
 
Table 4. Baseline and Week 8 Nutrient Intakes for Flaxseed and Control Groups. 
 Flaxseed 
n = 9 
 Control 
n = 8 
 Between 
Groups 
Variablea Baseline Week 8 Δb Baseline Week 8 Δb p-valuec 
Energy (kcal)d 1925±394 1862±334 -63 1937±474 1830±444 -107 0.630 
Total Fat (g)d 59±31 62±25 +3 53±26 55±145 +2 0.847 
Fiber (g)d 22±6 28±5 +5 26±5 31±4 4.1 0.191 
Sodium (mg)d 2148±619 1851±672 -296 2338±936 2185±662 -153 0.700 
a Data is represented as Mean±SD. 
b Δ represents absolute net change from baseline to week 8. 
c Data was analyzed as week 8 values minus baseline values (absolute net change); p-
value represents Mann-Whitney U non-parametric test. 
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d Student’s independent t-test analysis determined there were no significant differences at baseline 
between the flaxseed and control groups for kcals (p=0.958), fat (p-0.683), fiber (p=0.159), or sodium 
(p=0.624) 
 
4.3 Anthropometric Characteristics 
The effects of the 8 week intervention on anthropometric measurements are shown in 
Table 5. Body mass (kg), BMI (kg/m2), waist circumference (cm), and percent body fat 
were not significantly different between the flaxseed and control groups throughout the 
trial period. Additionally, there were no significant changes within groups. Both systolic 
and diastolic blood pressures were comparable between groups from baseline to week 8.   
 
 
 
 
 
 
 
 
 
 
Table 5.   Anthropometric Measurements from Baseline to Week 8. 
 Flaxseed 
n = 9 
 Control 
n = 8 
 Between 
Groups 
Variablea Baseline Week 8 Δb Baseline Week 8 Δb p-valuec 
Body Mass 
(kg) 
94.3±15.2 93.5±14.7 -0.8 85.9±21.2 85.8±21.4 -0.1 0.665 
BMI (kg/m2)d 31.7±4.2 31.4±4.1 -0.3 29.0±6.7 28.9±6.6 -0.1 0.152 
Waist 
Circumference 
(cm) 
104.9±12.7 102.2±11.9 -2.8 100.0±20.3 98.82±20.3 -2.5 0.809 
Body Fat (%) 
 
36.4±9.5 37.4±8.9 +1.0 33.3±8.2 33.9±9.1 +0.7 0.700 
Systolic BP 
(mm Hg)d 
 
141.8±8.9 140.4±11.6 -1.3 141.0±14.0 139.6±12.5 -1.4 0.735 
Diastolic BP 
(mm Hg)d 
76.1±3.9 74.6±3.9 -1.6 78.3±7.1 76.6±6.2 -1.6 0.961 
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a Data is represented as Mean±SD. 
b Δ represents absolute net change from baseline to week 8. 
c Data was analyzed as week 8 values minus baseline values (absolute net change); p-
value represents Mann-Whitney U non-parametric test. 
d Abbrevations: BMI, body mass index; BP, blood pressure. 
 
 
4.4 Biomarkers of Glucose Regulation 
 
Change in biomarkers of glucose regulation (fasting plasma glucose and insulin, HbA1c, 
and HOMA-IR) did not differ between groups (Table 6) from baseline to week 8. 
However, HbA1c, a measure of long term glucose control (2 to 3 months) demonstrated a 
modest decrease in the flaxseed group (p = 0.099) though not significant.  
 
 
 
 
 
 
 
 
 
 
Table 6. Changes in Markers of Glucose Regulation from Baseline to Week 8. 
 Flaxseed 
n = 9 
 Control 
n = 8 
 Between 
Groups 
Variablea Baseline Week 8 Δb Baseline Week 8 Δb p-valuec 
HbA1c 7.1±1.5 6.6±1.1 -0.5 6.7±2.0 6.8±2.6 +0.1 0.099 
Fasting 
Glucose 
(mg/dL) 
119.5±32.7 134.9±55.1 +15.4 130.7±62.2 129.1±69.1 -1.6 0.248 
Fasting 
Insulin 
(mg/dL) 
13.6±3.7 17.5±7.8 +4.0 14.6±5.8 19.2±13.5 +4.6 0.773 
HOMA-IRd 4.1±1.6 6.3±4.1 +2.2 5.0±3.1 6.8±6.6 +1.8 0.336 
a Data is represented as Mean±SD. 
b Δ represents absolute net change from baseline to week 8. 
c Data was analyzed as week 8 values minus baseline values (absolute net change); p-
value represents Mann-Whitney U non-parametric test. 
dHOMA-IR was calculated as (fasting glucose mg/dL x fasting insulin mg/dL)/405. 
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4.5 Serum Lipid Profile 
 
Comparisons of serum lipid profiles from baseline to week 8 between the treatment and 
control groups are shown in table 7. There were no significant differences found for any 
of the serum lipid markers including total cholesterol, LDL-C, HDL-C, total 
triglycerides, calculated VLDL-C (total triglycerides/5), or HDL:LDL ratios.  
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Table 7.  Changes in Measurements of Serum Lipids from Baseline to Week 8. 
 
Flaxseed 
n = 9 
 Control 
n = 8 
 Between 
Groups 
Variablea Baseline Week 8 Δb Baseline Week 8 Δb p-valuec 
Cholesterol 
(mg/dL) 
167.7±45.7 159.6±28.9 
 
-8.1 
 
173.5±43.7 166.1±40.8 -7.4 0.923 
LDL-C 
(mg/dL) 
105.5±53.7 100.0±36.2 
 
-5.5 
 
105.5±46.1 96.4±28.0 -9.1 0.773 
HDL-C 
(mg/dL) 
55.3±19.7 49.2±22.9 -6.1 
58.0±56.6 
 
56.6±36.2 
 
-1.4 
 
0.470 
VLDL-Cd 
(mg/dL) 
21.7±12.1 24.3±15.0 +1.5 20.1±6.5 22.5±5.6 +2.3 0.294 
Triglycerides 
(mg/dL) 
108.3±57.4 121.3±75.2 
 
+13.0 
 
128.9±76.9 134.4±138.6 +5.5 0.248 
HDL:LDL 
(mg/dL) 
0.6±0.2 0.6±0.2 +0.0 0.7±0.4 0.7±0.4 -0.1 0.149 
a Data is represented as Mean±SD. 
b Δ represents absolute net change from baseline to week 8. 
c Data was analyzed as week 8 values minus baseline values (absolute net change); p-value represents 
Mann-Whitney U non-parametric test. 
d VLDL-C was calculated as total triglycerides/5. 
 
 
4.6 Markers of Inflammation and Oxidative Stress 
 
There was a trend for decreased serum TNF-α concentrations in the flaxseed group as 
compared to the control (p = 0.060) from baseline to week 8 suggesting a tendency for 
decreased inflammation. There was also a modest decrease, though not significant 
observed between the flaxseed group and the control group from baseline to week 8 for 
TBARS, a marker of lipid peroxidation and oxidative stress (p = 0.083). A significant 
difference for NOx between groups from baseline to week 8 was not established.  
However, the flaxseed group had slightly higher concentrations of NOx at week 8 as 
compared to baseline (Δ = +5.7 nM/L vs. -2.41 nM/L for the control group). 
Measurements are shown below in table 8.  
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Table 8. Changes in Markers of Inflammation and Oxidative Stress from Baseline to 
Week 8. 
 
Flaxseed 
n = 9 
 Control 
n = 8 
 Between 
Groups 
Variablea Baseline Week 8 Δb Baseline Week 8 Δb p-valuec 
TNF-α 
(pg/mL)d 
0.1±0.0 0.06±0.02 -0.0 0.1±0.0 0.1±0.0 -0.0 0.060 
TBARS (nM 
MDA/L)d 
6.7±5.0 3.9±2.0 -2.8 2.9±1.4 2.8±2.0 -0.1 0.083 
NOx  
(nM/L)d 
5.9±1.6 11.7±3.5 +5.7 7.1±2.9 4.7±2.2 -2.4 0.092 
a Data is represented as Mean±SD. 
b Δ represents absolute net change from baseline to week 8. 
c Data was analyzed as week 8 values minus baseline values (absolute net change); p-
value represents Mann-Whitney U non-parametric test. 
d Abbrevations: TNFα, tumor necrosis factor-alpha; TBARS, thiobarbituric acid reactive 
substances; NOx, total nitrate/nitrites. 
 
 
4.7 Safety and Tolerability  
 
There were no reported issues with any complications arising from the test food volumes 
participants consumed during this nutrition intervention. The flaxseed group consumed 
28 g/d of ground flaxseed while the control group consumed 9 g/d of ground psyllium 
husk. All participants were instructed to report any discomfort, irritation, or aversions to 
the test foods at any time point throughout the study. No aversions to either test food or 
physical discomfort was reported.  
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CHAPTER 5 
DISCUSSION 
Lifestyle changes such as diet modifications and exercise as well as pharmaceutical 
interventions (i.e., insulin and hypoglycemic) are often implemented to control glucose 
metabolism during the initial treatment stages of T2D (i.e., stage I and stage II 
interventions, Lebovitz, 1999). In recent years there has been much attention paid to the 
potential benefits of various foods and their nutritive components in the management of 
T2D symptoms and associated outcome risks. Studies examining the effects of flaxseed 
consumption in its various forms (oil, ground, and whole seed) have provided mixed 
results in regards to these outcomes. Very few clinical trials looking at the impact of 
glycemic control and markers of inflammation in T2D participants have been conducted 
(Pan et al. 2007; Taylor et al. 2010). Furthermore, a comparison of the effectiveness of 
ground flaxseed as compared to psyllium supplementation in addition to a habitual diet in 
adult non-insulin dependent T2D participants has not been investigated. To the best of 
our knowledge, the present study is the first to investigate the effect of a modest amount 
of ground flaxseed compared to a fiber-matched control in conjunction to a person’s 
normal daily nutrient intake on glycemic control, lipid profiles, inflammation and 
vascular function in non-insulin dependent T2D patients. We demonstrated that eight 
weeks of supplementation with 28 g/d ground flaxseed in conjunction to an individual’s 
habitual diet demonstrated a mild increase in total NOx (p = 0.099) as well as a slight 
reduction in markers of inflammation (TNF-alpha, p = 0.060) and oxidative stress 
(TBARS, p = 0.083). Additionally, our findings resulted in a modest (though not 
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significant) decrease in HbA1c (p = 0.099) as compared to the control group (9 g/d 
ground psyllium husk). 
 
5.1 Measurements of Body Composition and Blood Pressure  
No changes in measurements of body composition (Table 5) were observed in either the 
flaxseed group or the control group from baseline to week 8. Our results confirm 
previous studies which failed to report any significance in measurements of body mass, 
BMI, body fatness, or waist circumference associated with flaxseed consumption 
(Hutchins et al. 2011; Rhee and Brunt, 2011) or lower doses (less than 12 g/d) of 
psyllium (Pal et al, 2011; Pittler and Ernst, 2004). Additionally, there were no changes in 
systolic or diastolic blood pressure of the non-insulin T2D participants enrolled in this 
study. To date, findings regarding the effects of flaxseed consumption on blood pressure 
have been inconclusive. Studies which have reported decreases in systolic BP, diastolic 
BP, or both have only done so in participants with baseline blood pressure values that 
were considered hypertensive (Paschos et al. 2007; Dupasquier et al. 2006).  
 
5.2 Glucose Regulation 
Type 2 diabetes is a chronic disease characterized by insulin insensitivity and 
hyperglycemia. Treatment and management of this disorder aims to control glucose 
regulation in the body, specifically to attenuate hyperglycemia in the bloodstream, as well 
as prevent the damage associated with prolonged tissue exposure to elevated blood 
glucose concentrations. Associated complications of T2D include macrovascular 
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complications (coronary artery disease, peripheral arterial disease, and stroke) and 
microvascular complications (diabetic nephropathy, neuropathy, and retinopathy). 
HbA1c, also known as glycated hemoglobin, is an indicator of long-term glycemic 
control over the past two to three months and is strongly associated with vascular 
complications, both macro- and micro-vascular (Fowler, 2008).  
While results from our current study suggested a modest decrease in HbA1c 
concentrations, these results were not significant (p = 0.099) and did not ascertain any 
major link between ground flaxseed consumption and long term glucose regulation. 
Moreover, since HbA1c is a long term marker of glucose control and reflects glucose 
regulation of the previous 2 to 3 months, short trials may find very little change in 
measured outcomes. Interestingly, one study that examined the effects of replacing a 
standard chow diet consisting of corn oil (1.2. mg/kg/d) with flaxseed oil (1.2 ml/kg/d) in 
streptozotocin (STZ)-induced diabetic rats and non-diabetic rats observed a significant 
decrease in fasting glucose and HOMA-IR levels in the STZ-treated diabetic group as 
compared to the STZ corn oil group and the control. However, the flaxseed supplemented 
STZ group did have increased (N.S.) fasting insulin levels compared to these same 
groups (Hussein et al. 2012).  Several clinical trials have failed to establish any link 
between low or high doses of flaxseed oil and glycemic control in type 2 diabetic patients 
(Barre et al. 2008; Goh et al. 1997; McManus et al. 2006). High doses of EPA and DHA, 
which as previously discussed can be metabolized from ALA, have been associated with 
deteriorated glycemic control in T2D (Glauber et al. 1998; Nettleton et al. 2005; 
Woodman et al. 2002).  
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Current research in animal and human studies (Hussien et al. 2012; Hutchins et al, 
2008; Rhee et al. 2011 Velqasquez et al. 2003) suggests the ground form of flaxseed, the 
form used in this current study, which is also rich in the ALA, as well as fibers, lignans, 
and folic acid may be useful in reducing hyperglycemia. Recent clinical trials have shown 
that ingestion of ground flaxseed (50 g/d, 10 weeks) resulted in statistically significant 
improvements in glycemic control in T2D patients as measured by fasting glucose, 
fasting insulin, and HOMA-IR (Bloedon et al. 2008). Furthermore, previous studies have 
demonstrated that ground flaxseeds improve glucose metabolism in healthy participants. 
In one study, healthy participants who consumed a baked product containing 50 g of 
flaxseed daily for 4 weeks had a 27% decrease in post-prandial glucose concentrations 
(Cunnane et al. 1993). Lemay (2002) found that ground flaxseed consumption (40 g/d for 
8 weeks) in post-menopausal hypercholestorelemic women resulted in significantly 
reduced blood glucose concentrations. Additionally, Hutchins et al, (2012) found that in 
obese pre-diabetic participants given 13 g/d or 26 g/d ground flaxseed, the 13 g/d group 
had improved fasting insulin levels as compared to the control (0 g/d) and higher flaxseed 
group (26 g/d), however, improvement were not seen in fasting glucose or HOMA-IR. 
Dahl (2005) demonstrated that healthy subjects who consumed flaxseed fiber in 
conjunction with their normal diet displayed attenuated peak glucose concentrations. In 
contrast, data from this current study did not establish any major effect on fasting glucose 
and insulin concentrations, or HOMA-IR. The focus of this trial was to examine the 
effectiveness of ground flaxseed (28 g/d) consumption as compared to the control test 
food (psyllium, 9 g/d) supplementation in non-insulin T2D participants as opposed to 
81 
 
previous trials which examined obese, pre-diabetic, or healthy participants which may 
account for the discrepancies in observed outcomes. Additionally, due to lack of research 
establishing an optimal dose for either dietary supplement as well as no known 
comparative trials examining the efficacy of flaxseeds versus psyllium, we have a lack of 
studies that we can directly compared our outcomes against. Furthermore, the 
mechanisms by which flaxseed exerts its control over glucose metabolism in the body 
have yet to be elucidated. Both the fiber components of flaxseed as well as the lignan 
concentration (i.e., SDG) may be responsible for results observed in prior studies.  
 
5.3 Serum Lipids 
Several studies have reported a positive impact of flaxseed consumption on lipid 
metabolism. Previous animal studies suggest that flaxseed or flaxseed derived lignans 
reduce both total and LDL-C as well as attenuate the progression of atherosclerosis 
(Lucas et al. 2004; Prasaad, 2008; Prasaad, 1999; Prasaad, 1997). In clinical trials, 
flaxseed consumption on blood lipid concentrations appear to be much more modest and 
the results lack consistency. Studies observing the effects of flaxseed oil in lipids profiles 
have reported decreases in total cholesterol and LDL-C. Harper et al. (2006) reported that 
3 g/d of flaxseed-derived ALA resulted in no significant differences between LDL-C 
levels, however, LDL-C subfractions LDL1 and LDL2, which are considered large 
buoyant LDL particles were significantly increased as compared to the smaller dense 
LDL subfractions which have a greater likelihood of oxidation and contributing to the 
progression of atherosclerosis. In hypercholesterolemic participants, ground flaxseed 
82 
 
supplementation (30 g/d, 12 weeks) and flaxseed-derived lignan supplementation (600 
mg/d, 8 weeks) has been associated with decreases in total cholesterol (7% and 22%, 
respectively) and LDL-C concentrations (10% and 24%, respectively). Most studies to 
date have not shown any impact of flaxseed consumption in any of its forms on HDL-C 
concentrations (Lemay et al. 2002; Harper et al. 2006; Stuglin et al. 2005),  with the 
exception of one trial (Bloedon et al. 2008) which reported a decrease in HDL-C in 
hypercholesterolemic men.  A meta-regression analysis of flaxseed supplementation in its 
various forms (Pan et al. 2009) analyzing a total of 28 clinical trials (overall participants 
= 1539) demonstrated that of the 13 out of 28 trials which used flaxseed oil, no 
significant changes in total and LDL cholesterol were detected. Flaxseed in whole or 
ground form were used for ten of these 28 studies and flaxseed derived lignan trials 
comprised five of the 28 studies. Whole flaxseed and flaxseed lignans demonstrated a 
greater impact on serum lipids as compared to ground flaxseed. Of the reported trials 
which used flaxseed in its whole form or lignans derived from flaxseed there were 
significant decreases in total cholesterol and LDL-C concentrations, however this 
reduction was much greater in studies including post-menopausal women and these 
reductions were only moderate for trials that included both women and men. In 
agreement with our findings the authors found no association between flaxseed in any 
form or flaxseed derived lignans on HDL-C concentrations. Results from this analysis 
suggested that sex, type of intervention (whole flaxseed, flaxseed oil, or lignan 
supplement), and initial lipid concentrations (i.e., healthy subjects vs. 
hypercholestorelemic subjects) influenced the net changes in total and LDL cholesterol.  
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Trials examining the effects of flaxseed consumption have also displayed varying 
outcomes. While epidemiological data reports higher levels of ALA consumption  
associated with lower total triglyceride levels (Dejousse et al. 2005), flaxseed clinical 
trials have reported an increase (Cunnane et al, 1995), decrease (Dejousse et al. 2003; 
Zhao et al. 2004), or no change (Rallidis et al. 2003; Paschos et al. 2007) on total 
triglyceride levels.    
 
5.4 Inflammation and Oxidative Stress  
Oxidative stress resulting from increases in inflammation, dyslipidemia, and 
hyperglycemia is also strongly associated with worsening of T2D symptoms and 
associated complications. There is strong evidence of increased platelet aggregation in 
type 2 diabetes which may be a result of ROS generation and oxidative stress (Ferroni et 
al. 2004). As we demonstrated in this study there was a trend for decreased serum 
concentrations of the inflammatory marker TNF-alpha in the flaxseed group (p = 0.060) 
as well as a modest decrease in plasma concentrations of TBARS (p = 0.083) which 
suggests decreased lipid peroxidation.  While not significant, possibly due to the 
relatively small sample size or participant characteristics, these results appear to 
corroborate with previous findings which demonstrated flaxseed consumption in animal 
models (Dupasquier et al. 2007; Hussein et al. 2012) and clinical trials (Allman et al. 
1995; Bierenbaurn et al. 1993; Freese et al. 1994; Pilar et al. 2014; Rhee and Brunt, 2011) 
act to decrease concentrations of platelet aggregation (i.e., VCAM, ICAM, VEGF), 
inflammation (TNF-alpha, IL-6) and oxidative stress (TBARS) in healthy, obese, and 
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glucose-intolerant individuals. Findings from the previous studies suggest a protective or 
antioxidant effect of flaxseeds which is in agreement with the findings of the present 
study.  Increased glucose oxidation and lipid peroxidation as a result of hyperglycemia 
and obesity increases inflammation, ROS generation, and oxidative stress (Furukawa et 
al. 2004). Increased oxidative stress may inhibit proper phosphorylation of the insulin 
receptor or decrease the translocation of GLUT4 on the cell membrane through impaired 
insulin signaling intermediates (Hoehn et al. 2009; Rudich et al. 1998). It was found that 
antioxidants attenuate impaired GLUT4 translocation and increase glucose uptake 
(Estrada et al. 1996; Shin et al. 2006). Increases in ROS, such as superoxide lead to 
increases in oxidative stress through scavenging of nitric oxide (NO) to form 
peroxynitrite, which is strongly associated with vascular dysfunction. Furthermore, cells 
other than the endothelium, which produces NO as a vasodilator for vascular smooth 
muscle, such as macrophages, can produce NO in very small quantities as a defense 
against inflammation and oxidative stress. High physiological concentrations of NO in 
the body favor increases in oxidative stress thus worsening symptoms associated with 
T2D. We measured total plasma concentrations of nitrates and nitrites (NOx) since 
nitrates are rapidly metabolized to nitrites in vivo. Consistent with our findings for TNF-
alpha and TBARS concentrations, there was a slight increase in plasma concentrations of 
NOx (p = 0.099) following the 8 week supplementation with ground flaxseed. These 
modest reductions in levels of inflammation and oxidative stress may be attributed to the 
SDG content in flaxseed which previous studies have reported to decrease lipid 
peroxidation due to its ability to scavenge ROS (Houstis et al. 2006). This present study 
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did not specifically examine serum concentrations of SDG in the flaxseed group as 
compared to the control and only a few clinical trials have examined SDG in flaxseeds on 
oxidative stress, thus greater investigation is warranted.  
 
5.5 Study Limitations and Strengths  
The current study did have some limitations. Few studies have been conducted in regards 
to flaxseed and T2D. It is possible that our study may have lacked statistical power to 
detect changes in outcomes of interest. The sample size calculation estimated that at least 
16 subjects would be necessary for this study to have sufficient statistical power for 
detecting changes in HbA1c and fasting plasma glucose. Recruitment was increased in 
order to assure that the minimum sample size was achieved. The sample size calculation 
was based on two previous studies Hutchins et al. (2012) and Pan et al. (2007) which 
specifically examined the effects of ground flaxseed consumption in diabetic participants 
on measures of glycemic control. It is possible that the effect sizes based on that study 
may have been overestimated due to differences in study design (parallel arm trial as 
compared to randomized crossover study).  
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Our study failed to achieve an effect size greater than 55% using a Mann-Whitney 
U analysis, which strongly suggests that additional participants were needed to truly 
observe any valid changes between groups. Additionally, of the few clinical trials that 
have looked at the effects of whole or ground flaxseed consumption on similar outcome 
variables, dosage of flaxseed ranged from 20 g/d to 50 g/d and lasted from 2 weeks up to 
12 weeks in length, thus a known optimal dosage has yet to be established. This study 
included participants who were on oral hypoglycemic medications (i.e., metformin, 
flaxseed 5/9; control 6/80) and allowed for participants to be on statins or fibrolytics 
(flaxseed, 7/9; control 6/8) which may have effected changes seen in lipid variables, 
although participants were instructed to maintain consistent use of medications to avoid 
this issue. The majority of previous trials examining the effects of flaxseeds on serum 
lipids had participants with higher total-and LDL-C concentrations at baseline in addition 
to specifically examining hypercholestorelemic populations. When performing a 
statistical analysis for changes in the primary outcomes (HbA1c and fasting plasma 
glucose) from the present study to conduct a power analysis, the suggested sample size 
for having a statistical power (at a 0.05 significance level and power > 0.80) was 15 
participants in both the flaxseed and control group (N = 30). Since two to three months 
are often necessary to observe changes in HbA1c it is possible that greater effects would 
have been observed if the participants had consumed the flaxseed for a long period of 
time. A longer intervention time would have also provided more information regarding 
adherence of individuals to flaxseeds supplemental to a normal diet. Additionally, we 
relied on self-reported nutrient intake data to estimate dietary measurement using 3-day 
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food records. While this questionnaire has been validated (Pietinen et al. 1988) and is not 
reliant on memory recall there may be issues with participants underestimating food 
quantities and underreporting portions. Other clinical nutrition interventions have 
circumvented this issue by structuring a complete diet program for study participants as 
well as providing comprehensive dietary instructions (Serra-Majem et al. 2006). The 
present study has a number of strengths worth discussing. For all subjects who completed 
the baseline fasting blood draw there was minimal attrition (17 out of 19, 85%) from 
baseline to week 8 which is less than the anticipated participant attrition rate (20%). 
Additionally, in this randomly controlled trial, subjects (all non-smokers with a diagnosis 
of T2D ≥ six months) were matched based upon baseline height, weight, HbA1c, sex, and 
age then randomly assigned to their respective group to eliminate confounding variables 
affecting between group measured outcomes. Subjects were blinded to their study 
condition which further decreases likelihood of performance bias or attrition bias 
disrupting the validity of this intervention trial. Furthermore, body composition and 
nutrient intakes for each group was comparable within group and between groups from 
baseline to week 8 reducing the likelihood of an interaction effect of weight loss or 
changes in body fatness on measures of glycemic control, serum lipids, and 
inflammation. Additionally, there was little between group variations which increased 
validity of measured outcome data between groups. 
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5.6 Future Research 
This current study was conducted in order to investigate the effects of flaxseed use on 
complications of T2D. Future studies should include a larger sample size in addition to a 
tightly structured randomized control trial with an expanded participant sample 
population to include subjects with pre-diabetes and MetS to determine variations in the 
effectiveness of flaxseeds on specific populations. Additionally, this study did not 
measure plasma concentrations of polyunsaturated fatty acids ALA, EPA, DHA, or the 
flaxseed-derived lignan SDG. As these bioactive components have been proposed as 
potential mechanisms by which flaxseeds may exert their effect, future analyses should 
include these measures. Additionally, plasma levels of alpha-tocopherols should be 
measured in future studies to elucidate the potential antioxidant protective effects of 
flaxseeds in the progression of T2D.  
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CHAPTER 6 
CONCLUSIONS 
Due to the prevalence and economic burden of diabetes and its associated CVD risks, 
research is needed to assess the safety and effectiveness of treatment strategies. Nutrition 
interventions that are simple and effective in reducing symptoms of diabetes are an area 
of great interest due to the relative low cost and accessibility to the general public. 
However, diets are not limited to a single food; likewise, foods such as flaxseeds are not 
limited to a single nutrient thus complicating the mechanistic properties and health 
benefits of a particular food on any given population. The primary aims of this study 
were to investigate the effects of consuming 28 g/d ground flaxseed in addition to a 
participant’s habitual diet for eight weeks on markers of glycemic control in T2D. 
Additionally, we further investigated the effects of ground flaxseeds on serum lipid 
concentrations as well markers of inflammation and oxidative stress in subjects with non-
insulin dependent T2D. Due to the lack of knowledge regarding the use and efficacy of 
modest consumption of ground flaxseeds at attenuating symptoms associated with T2D, 
additional exploratory outcomes included evaluating compliance as well as the efficacy 
of incorporating a moderate amount of flaxseed into the daily diets of individuals with 
non-insulin T2D as compared to previous studies which used larger volumes (50 g/d) of 
ground flaxseed. 
To our knowledge this study is the first to examine a moderate amount of ground 
flaxseeds on glycemic control, serum profiles, and markers of inflammation and 
oxidative stress in T2D participants. We did not confirm the main hypothesis that 28 g/d 
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of flaxseed intake would result in significantly improved glucose regulation, however, we 
did demonstrate a trend towards reduced markers of inflammation (NOx, TNF-alpha) and 
oxidative stress (TBARS) which is consistent with previous literature. Additionally, it 
should be noted 28 g/d of ground flaxseed did not result in any negative effects and was 
favorably reported by study participants thus increasing the likelihood that the dosage 
was reasonable and could be assimilated into a habitual diet. Lack of significant findings 
in this study may be related to the small study sample size, length of trial, or mechanism 
by which flaxseeds exert their greatest effects. The latter requires further investigation to 
elucidate the populations that may potentially benefit the greatest from ground flaxseed 
interventions.   
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* 1. Please provide your email address. 
 
2. Has your physician diagnosed you with type 2 diabetes? 
Yes 
No 
Not sure 
3. Do you know your glycosylated hemoglobin A1c level? 
Yes 
No 
Not sure 
If yes, what is it?  
4. Are you between 18 and 75 years old? 
Yes 
No 
5. Are you currently taking insulin? 
Yes 
No 
Not sure 
6. Are you currently taking any oral diabetic medications (e.g., 
metformin)? 
Yes 
No 
7. Do you take any of the following medications: e.g. beta-blockers, ACE 
inhibitors, diphenhydramine or cyproheptadine (allergy medications), 
lithium carbonate, corticosteroids, thiazolidinediones ( Actos, Avandia or 
Avandamet), sulfonylureas, biguanides, meglitinides, incretins, sodium 
valproate, or thyroid replacement therapy? 
Yes 
No 
Not sure 
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8. Are you currently pregnant or breast-feeding? 
Yes 
No 
9. Do you have any known food allergy? 
Yes 
No 
Not Sure 
If yes, please specify  
10. Would you be willing to consume 4 tablespoons of ground flaxseeds or 
1.5 tablespoons pysllium fiber daily for 8 weeks? 
Yes 
No 
11. Will you be able to maintain your current diet and physical activity for 
a consecutive 8 weeks? 
Yes 
No 
Not sure 
12. Do you train athletically to compete? 
Yes 
No 
13. Are you willing and are able to travel to the ASU Downtown Campus 
to meet with the research investigators on three separate mornings? 
Yes 
No 
14. Are you willing to have a fasting blood draw (fast 10-12 hours prior to 
blood draw) on 2 separate occasions? 
Yes 
No 
Not Sure 
15. Where did you hear about this survey? 
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Medical History Questionnaire 
 
            ID#________________ 
                       Age:________ 
                                                                                               Height:_______ft. _______in. 
           Waist:________in.  
Gender (please circle):  Female    Male            Weight:__________lbs.  
Smoker (please circle):  Yes No    
          
1.  Are you taking any medications regularly? (Including aspirin, steroids, birth control, 
etc.) Y     N 
 If yes, what medications and how often? 
 
 
 
2. Do you currently take supplements? (vitamins, minerals, herbs, etc.)   
 Y     N 
 If yes, what supplements and how often? 
 
 
 
3. Do you take insulin or an oral diabetic control medication (e.g., metformin)?  
 Y     N 
4. Do you know what your glycosylated hemoglobin A1C (HbA1c) level is?  
   Y     N 
 If so, what is it?_______________________________ 
 
5. Has a doctor ever told you that you have any of the following conditions? 
To be 
completed 
by 
investigator 
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       Heart disease?  Y     N     Thyroid problems?
 Y     N 
       Kidney disease?  Y     N     Cancer?  
 Y     N 
       Liver disease?  Y     N     High blood pressure?
 Y     N 
       Food Allergy?  Y     N (if yes, what 
type?)______________________________ 
       Type 2 Diabetes?                Y     N (if yes, when were you 
diagnosed?)_________________ 
       Other chronic 
conditions?__________________________________________________ 
 
6. Are you pregnant or planning on becoming pregnant in the next 16 weeks?  
 Y     N 
7. Are you currently breast-feeding?       
 Y     N 
8. Have you ever fainted at a blood draw?      
 Y     N 
Are you willing to participate in a blood draw?     
 Y     N 
 Have you donated blood in the past 8 weeks?     
 Y     N 
9. Will you be willing to consume 4 tablespoons (40 g) of flaxseeds 5-7 times per week 
for 8 weeks?           
  Y     N 
 
10. Would you be willing to consume 1.5 tablespoons (18 g) of pysllium powder 5-7 per 
week for 8 weeks?          
  Y     N 
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11. Do you follow a specific diet? (weight loss/gain, vegetarian, low-fat, etc.)  
 Y     N 
 
12. Are you willing to drive or take the Phoenix light rail (metro system) to the ASU 
downtown Phoenix campus for a fasting blood draw on 2 separate occasions?   
   Y     N 
 
13. Will you have a problem fasting overnight (10-12 hr) prior to the blood draw? 
 Y     N  
 
14. Will you be able to maintain your typical lifestyle/activities during the trial?  
 Y     N 
 
15. Over a 7 day period, how often do you engage in any regular activity long enough to 
work up a sweat   
      (e.g., heart beats rapidly)?_________________ How often do you exercise 
moderately per    
      week?___________ 
 
16. Please circle the total time you spend in each category for an average week. 
 
               Light activities such as: slow walking, golf, easy swimming, gardening, etc. 
           Hours per week: 0   1   2   3   4   5   6   7   8   9   10+ 
               Moderate activities such as: moderate walking, cycling, swimming, weight 
lifting, etc. 
           Hours per week: 0   1   2   3   4   5   6   7   8   9   10+ 
                Vigorous activities such as: fast walking, jogging, cycling, heavy/intense 
weight lifting, etc. 
           Hours per week: 0   1   2   3   4   5   6   7   8   9   10+ 
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17. Please describe any other medical conditions or situations that may affect you ability 
to participate  in a research trial (i.e., pregnancy, infections, travel, deadlines, etc.). 
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APPENDIX G 
INSTRUCTIONS FOR TEST FOOD STORAGE AND CONSUMPTION
132 
 
Consuming plant-based fibers 
1. Store the fiber supplement in the freezer, refrigerator, or other cool dry 
area such as the pantry. Try to avoid exposure to direct sunlight. 
2. Consume 1 package of the fiber supplement 5-7 days per week for the 
eight weeks. 
3. Fiber can be consumed at one time or split up throughout the day (e.g., 1 T 
in breakfast oatmeal, 2 tsp in lunch salad dressing, 1 T in dinner chili, and 2 tsp 
sprinkled over ice cream). You can divide up the fiber any way you choose as 
long as you consume the entire package during the course of the day. 
Adding ground fibers to your daily diet 
1. Add ground flaxseed or psyllium powder to yogurt, applesauce, soups,  
or smoothies. 1-2 tablespoons does not alter the flavor very much of the yogurt 
or smoothie. This will also add fiber to your yogurt or smoothie.  
2. Bake with flaxseed or psyllium powder. Both fibers go well in baked 
goods at small or larger amounts. It imparts a toasted nut flavor that matches 
well in sweet or savory baked goods. Some popular baked uses of flaxseed are in 
breads or muffins. It has a good heat stability so all the nutrients are available 
after the baking process and is a good way to get extra fiber in a baked item 
without affecting texture and taste dramatically. 
3. Add one or two spoonfuls into chili, spaghetti sauce, stew, or gravy. 
4. Add to commonly used condiments. Each blends well in mayonnaise, 
mustard and ketchup. It also goes great in salad dressings and as a salad 
topping. You will not need to add very much (1 tablespoon or less will suffice). 
5. Mix into oatmeal or cream of wheat cereal. 
6. Sprinkle on top of toast with peanut butter and bananas or jelly. 
7. Sprinkled on top of salads, mixed in to mashed potatoes, etc. 
8. Add to drinks. Using smaller amounts throughout the day in whatever 
you are drinking will give just as much, without the thickness from one larger 
dose. 
9. Stir a little into juice and drink up. 
10. Sprinkled on top of fruit, pudding, or ice cream for dessert. 
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APPENDIX H 
  3-DAY FOOD RECORDS 
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DIETARY INTAKE RECORD 
ASU Flaxseed Study 
 
Day of Week:     Su   M   T   W   Th   F   Sat                                             (circle one) 
TIME OF 
MEAL 
FOOD ITEM 
DESCRIPTION (how was it 
prepared or where was it 
purchased?) 
AMOUNT 
(cups, oz, tsp, 
etc.) 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
    
TIME OF 
MEAL 
FOOD ITEM DESCRIPTION (how was it 
prepared or where was it 
AMOUNT 
(cups, oz, tsp, 
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*Supplements Taken – List brand, number of tablets/amount: 
 purchased?) etc.) 
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APPENDIX I 
COMPLIANCE CALENDAR 
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Sun Mon Tue Wen Thu Fri Sat 
1 2 3 4 5 1 2 
3 4 5 6 7 8 9 
10 11 12 13 14 15 16 
17 18 19 20 21 22 23 
24 25 26 27 28 29 30 
31       
  
 S
e
p
te
m
b
e
r 
  
2014 
INSTRUCTIONS 
 
1. Check off each day indicating that the study food was consumed as instructed. 
2. Arrive at the Nutrition labs at scheduled times for testing. 
3. 12 hours prior to your blood draws: 
• Do not exercise strenuously although you may walk the dog and carry out routine activities.                      
• Beginning at about 10:00 pm, do not eat or drink anything other than water.   
4. At study weeks 0 and 8, bring your diet records with you to the lab.  
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APPENDIX J 
MODIFIED TBARS PROTOCOL 
 
139 
 
TBARS Assay (Zeptometrix, Buffalo, NY) can be used with either plasma or serum (both 
heparin and EDTA) 
Plasma: Collect fasting heparinized whole blood. Centrifuge at 3500 rpm 
for 10 min at 5-10°C, carefully remove plasma and place on ice for 
immediate analysis or freeze several aliquots at -70°C for later analysis. 
Samples can be safely stored for 1-2 months. Process as described below 
for serum. 
Serum: Collect fasting whole blood in a red top vacutainer®. Incubate at 
room temperature for at least 30 min for clots to form. Centrifuge at 3500 
rpm for 10 min. Carefully remove serum and place on ice for immediate 
analysis or freeze aliquots at -70°C for later analysis.  
Protocol: All solutions must be at room temperature before performing the assay. If using stored 
samples, thaw on ice. Label tubes for standards (0-4) as well as samples. Poke holes in the top to 
avoid excessive pressure build-up during heat block phase.  
Using the Zeptometrix TBARS assay kit prepare the following: 
Set the heat block to 95ᵒC 
To make TBA buffer: 
• To 10 mL Diluent 1 add 106 mg TBA powder (cover with parafilm) 
• Mix on a hot plate at a low temperature (45-55ᵒC) 
• Turn off the plate (allow to cool), add 10 mL of Diluent 2, mix for 10 min on stir plate 
with heat off. 
Prepare Standards: 
• Prepare standards according to Table 1 (make sure to add MDA standard to Diluent). 
Standard MDA standard (uL) MDA Diluent (uL) Final Conc 
0 0 100 0 
1 12.5 87.5 12.5 
2 25 75 25 
3 20 50 50 
4 100 0 100 
 
• Once samples are prepared place on ice, they can now be treated the same as the 
samples. 
 
Prepare Samples: 
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1. In labeled eppendorf tubes with hole (use 18-20G needle) prepared sample 
2. Mix sample for duplicate runs 
3. Add 30 uL of sample 
4. Add 30 uL of SDS buffer 
5. Add 750 uL of TBA buffer 
6. Vortex tubes 
7. Place on heat block @ 95ᵒC for 60 minutes 
8. Place on ice for 10 minutes 
9. Centrifuge samples (NOT STANDARDS) @ 3000 rpm for 15 minutes @ RT 
Load 96 well plate: 
a. Add 200 uL of supernatant to plate well in duplicates (making sure not to disturb the 
pellet formed on the bottom of the tube) 
b. Absorbance reading: read supernatants on plate reader @ 532 nm 
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APPENDIX K 
INDIVIDUAL VARIATIONS IN MEASURES OF BODY COMPOSITION, BLOOD 
PRESSURE, AND NUTRITENT INTAKE FOR FLAXSEED GROUP 
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A. Individual changes in waist circumference (in) from baseline to week 8. 
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B. Individual changes in BMI (kg/m2) from baseline to week 8. 
144 
 
 
 
 
B. Individual changes in body fatness (%) from baseline to week 8. 
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D. Individual changes in systolic blood pressure (mm Hg) from baseline to week 
8. 
146 
 
 
 
 
E. Individual changes in diastolic blood pressure (mm Hg) from baseline to week 
8. 
147 
 
 
 
 
F. Individual changes in total energy (kcal) intake from baseline to week 8. 
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G. Individual changes in total fat (g) intake from baseline to week 8. 
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H. Invidual changes in total fiber (g) intake from baseline to week 8. 
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I. Individual changes in sodium (mg) intake from baseline to week 8. 
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APPENDIX L 
INDIVIDUAL CHANGES FOR MEASUREMENTS OF BODY COMPOSITION, BLOOD 
PRESSURE, AND NUTRIENT INTAKE FOR CONTROL GROUP 
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A. Individual changes in waist circumference (in) from baseline to week 8. 
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B. Individual changes in BMI (kg/m2) from baseline to week 8. 
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C. Individual changes in body fatness (%) from baseline to week 8. 
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D. Individual changes in systolic blood pressure (mm Hg) from baseline to week 
8. 
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E. Individual changes in diastolic blood pressure (mm Hg) from baseline to week 
8. 
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F. Individual changes in total energy (kcal) intake from baseline to week 8. 
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F. Individual changes in total fat intake (g) from baseline to week 8. 
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G. Individual changes in total fiber (g) intake from baseline to week 8. 
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H. Individual changes in sodium (mg) intake from baseline to week 8. 
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APPENDIX M 
INDIVIDUAL CHANGES IN MEASUREMENTS OF GLUCOSE REGULATION FOR 
FLAXSEED GROUP 
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A. Individual changes in HbA1c (%) from baseline to week 8. 
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B. Individual changes in fasting plasma glucose (mg/dL) from baseline to week 
8. 
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C. Individual changes in fasting insulin (mg/dL) from baseline to week 8. 
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D. Individual changes in HOMA-IR from baseline to week 8. 
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APPENDIX N 
INDIVIDUAL CHANGES IN MARKERS OF GLUCOSE REGULATION FOR CONTROL 
GROUP 
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A. Individual changes in fasting plasma glucose (mg/dL) from baseline to week 
8. 
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B. Individual changes in fasting insulin (mg/dL) from baseline to week 8. 
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C. Individual changes in HOMA-IR from baseline to week 8. 
170 
 
 
 
 
 
 
 D. Individual changes in HbA1c (%) from baseline to week 8. 
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APPENDIX O 
INDIVIDUAL CHANGES IN SERUM LIPID MEASUREMENTS FOR FLAXSEED GROUP 
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A. Individual changes in total cholesterol (mg/dL) from baseline to week 8. 
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B. Individual changes in HDL-C (mg/dL) from baseline to week 8. 
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C. Individual changes in LDL-C (mg/dL) from baseline to week 8. 
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D. Individual changes in total triglycerides (mg/dL) from baseline to week 8. 
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E. Individual changes in calculated VLDL (mg/dL) from baseline to week 8. 
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APPENDIX P 
INDIVIDUAL CHANGES IN SERUM LIPIDS MEASUREMENTS FOR CONTROL GROUP 
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A. individual changes in total cholesterol (mg/dL) from baseline to week 8.  
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B. Individual changes in HDL-C (mg/dL) from baseline to week 8.  
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C. Individual changes in LDL-C (mg/dL) from baseline to week 8.  
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D. Individual changes in total triglycerides (mg/dL) from baseline to week 8.  
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E. Individual changes in calculated VLDL (mg/dL) from baseline to week 8.  
183 
 
APPENDIX Q 
INDIVIDUAL CHANGES IN MARKERS OF INFLAMMATION FOR FLAXSEED GROUP 
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A. individual changes in plasma concentrations of TNF-alpha (pg/mL) from 
baseline to week 8. 
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B. Individual changes in serum concentrations of TBARS (MDA nM/L) from 
baseline to week 8. 
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C. Individual changes in plasma concentrations of TBARS (nM/L) from baseline 
to week 8. 
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APPENDIX R 
INDIVIDUAL CHANGES IN  MARKERS OF INFLAMMATION FOR CONTROL GROUP 
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A. Individual changes in plasma TNF-alpha concentrations (pg/mL) from baseline 
to week 8.  
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B. Individual changes in serum TBARS concentrations (MDA nM/L) from baseline 
to week 8.  
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C. Individual changes in plasma NOx concentrations (nM/L) from baseline to week 
8.  
